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Abstract 
 
Background:  Commercial bioprosthetic heart valves (BHVs) are generally produced 
from porcine aortic heart valves or sewn from bovine pericardium.  BHVs are durable in 
older patients, but in younger patients they are subject to age-dependent structural 
valve degeneration (SVD).  SVD involves tissue calcification, which our research 
suggests is due in part to an immune mediated BHV injury caused by high levels of 
xenogeneic antigen galactose-alpha-1,3-galactose (α-Gal) on commercial valves and 
anti-Gal antibody universally present in patients.  This suggests that α-Gal-free BHVs, 
unaffected by anti-Gal antibody could resist calcification and show improved durability 
in younger patients. 
Aim:  This research was to develop quantitative methods to measure α-Gal antigen on 
animal tissue and further characterize the role of α-Gal-specific immune injury in tissue 
calcification.   
Methodology:  I tested an α-galactosidase based colorimetric enzymatic assay for 
detecting galactose liberated from tissue and an α-Gal-specific inhibition ELISA (GIE) 
to measure α-Gal on fixed porcine pericardium.  The α-Gal levels on wild type (WT), 
and α-Gal-free (GTKO) porcine tissue after glutaraldehyde fixation and after treating 
with various anticalcification processes were measured.  The effects of anti-Gal 
antibody on WT and GTKO tissue calcification were measured using subcutaneous 
implants in anti-Gal antibody producing GTKO mice.  
Results: The α-galactosidase based colorimetric assay showed low sensitivity and was 
not pursued.  The GIE, using two different anti-Gal reagents, was sensitive and 
reliable.  A-Gal antigen levels, measured by GIE were not reduced by anticalcification 
processing.  Minimal tissue calcification was observed in GTKO mice for both WT and 
GTKO tissue.  There was no clear anti-Gal immune response to WT implants.   
Conclusion: This research shows that the current BHVs remain susceptible to immune 
injury as α-Gal antigen is not eliminated by the current anticalcification treatments.  In 
addition caution is required when choosing the appropriate animal model to address 
the immune response factor in tissue calcification studies. 
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1 Introduction 
1.1 Prosthetic heart valves 
Heart valve disease constitutes a significant part of cardiovascular diseases 
which are the number one cause of death in the developed world (Simionescu 
2004).  Treatment of valvular heart disease comprises approximately 20% of all 
cardiac surgery.  Surgery options include repairing the valve or replacing the 
valve.  Annually more than 250,000 heart valves are implanted worldwide 
(Siddiqui et al. 2009).  There are four valves in the human heart - the mitral, 
tricuspid, aortic and pulmonary valves.  Aortic and mitral valves are the most 
frequently damaged in part due to the higher pressure they experience.  The 
main causes for heart valve dysfunction are senile degeneration, genetic 
abnormalities and infective endocarditis.  In the developing world there is high 
incidence of rheumatic heart disease which can lead to heart valve dysfunction 
in children and young adults (Zilla et al. 2008).  The need for heart valve 
replacement is increasing in proportion to the demographics of an aging global 
population.  In addition the growing emergence of wealth in developing nations 
with its concomitant improvement in healthcare further increases the demand 
for cardiovascular healthcare (Zilla et al 2008). 
The most common treatment for heart valve dysfunction is heart valve 
replacement.  Currently there are two types of clinical prosthetic heart valves - 
biological heart valves (BHVs) and mechanical heart valves (MHVs) (Figure 
1.1).  Clinical heart valve replacements using BHVs started in the early 1960s, 
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when unfixed aortic valves from human cadavers were implanted into patients 
and functioned normally for up to six years prompting their use by more 
cardiothoracic surgeons (BARRATT-BOYES 1964;KERWIN et al. 1962).  Due to 
the shortage of human valves heart valve replacement was subsequently 
attempted using porcine heart valves.  Marian Ionescu was the first who used 
aortic valves from pigs to construct valve replacements for use in humans at the 
General Infirmary at Leeds and Leeds University.  Porcine valves were initially 
treated with formalin for sterilisation, preservation of tissue and prevention of 
autolysis (Ionescu et al. 1968;Rose 1972).  Formalin fixed valves had a high 
failure rate, which was associated with mononuclear and multinuclear cell 
infiltration (Albert et al. 1977;Ionescu et al. 1972).  In failed valves valvular 
incompetence was caused by stretching and deformation of the cusps resulting 
from denaturation of collagen within 2-32 months implantation (Rose 1972).  
The use of animal heart valves to treat patients became effective only after the 
introduction of glutaraldehyde fixation (Albert et al. 1977).  Glutaraldehyde is a 
crosslinking reagent which reacts with the ε-amino groups of amino acids of 
collagen and other proteins through a Schiff-base reaction to produce intra- and 
inter- molecular crosslinks (Bezuidenhout et al. 2009).  Crosslinking reduces 
immunogenicity of proteins, preserves structural integrity of the valve and 
serves as a sterilizer.  The Hancock valve fixed in 0.2% glutaraldehyde 
(Medtronic Heart Valves, Santa Ana, CA) was the first glutaraldehyde fixed 
clinical BHV to be introduced in the market.  This was followed by the 
Carpentier-Edwards porcine valve (Baxter Cardiovascular, Santa Ana, CA) fixed 
in 0.6% glutaraldehyde (Schoen and Levy 1999).  Since that time heart valve 
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replacement has become common practice, however, manufacture of animal 
based BHVs remains largely based on glutaraldehyde fixation (Zilla et al. 2008). 
Currently BHVs are made from either human heart valves (homografts) that 
are usually cryopreserved, or glutaraldehyde fixed porcine aortic heart valves or 
assembled from glutaraldehyde fixed bovine pericardium (heterografts).  BHVs 
are generally three-leaflet valves, mounted on a synthetic stent and surrounded 
by a sewing ring at their base (stented valves) (Schoen & Levy 1999).  
Examples of stented BHVs include Hancock, Epic Supra (St Jude Medical, 
Minnesota, USA), Mosaic (Carpentier–Edwards).  In other instances stentless 
valves are produced.  Stentless valves were developed for aortic valve 
replacement, where their larger orifice area offers better hemodynamic 
performance and reduced mechanical stress (Butany et al. 2006;David et al. 
1988).  Examples of stentless valves include the Toronto porcine stentless 
valve and Medtronic Freestyle.  Stented or stentless, the main advantage of 
BHVs is their low level of thrombogenicity, such that they generally do not 
require chronic anticoagulation (Schoen & Levy 1999).  Largely because of their 
low thrombogenic potential BHVs constitute nearly 60% of the implanted valves 
and the percentage is growing. 
Mechanical valves are made from non-biological materials (metal, plastic, 
carbon).  The use of these non-biological materials causes the MHV to be 
prothrombotic, as circulating platelets are spontaneously activated on contact 
with non-biological surfaces.  Exposure of the synthetic surfaces to blood 
circulation leads to activation of the coagulation and complement systems 
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(Nilsson et al. 2010).  As a consequence MHVs require lifelong anticoagulation 
treatment.  Anticoagulation is often achieved using Coumadin and is associated 
with a high risk of spontaneous bleeding if the dosage is too high and 
thrombotic occlusion if the dose is too low (Cannegieter et al. 1994).  Thus 
mechanical valves impose lifestyle restrictions leading to reduced participation 
in activities (work and leisure), which makes their application less desirable 
especially for young patients and patients with physically demanding 
professions.  Moreover, young patients in the developing world where the 
frequency of infection related valve disease may be high, may have no effective 
treatment if the infrastructure for monitoring anticoagulation is not in place 
(Manji et al. 2012). 
 
 
Figure 1.1  Commercial BHVs.  Medtronics Hancock II is 
  a biological and St.Jude Regent a mechanical heart valve. 
 
Stented BHVs and mechanical heart valves are surgical valves which require 
intensive open heart surgery.  Not all patients, especially older and high-risk 
patients can withstand this surgery.  Recently a new valve design and delivery 
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method was developed to permit the percutaneous implantation of a 
replacement heart valve, the transcatheter valves.  Their use has gradually 
been introduced in intermediate and low risk patients but their performance and 
durability remains to be determined (Hamm et al. 2015). While the collapsible 
design of these valves is unique, the tissue used to construct the valve remains 
glutaraldehyde fixed porcine pericardium. 
1.2 BHV degeneration 
Although BHVs do not require chronic anticoagulation and thereby offer an 
attractive alternative to mechanical prostheses, they degenerate.  The single, 
greatest predictor of BHV degeneration is patient age.  BHVs in patients older 
than 65 years of age are durable with approximately 10% structural valve 
degeneration (SVD) in 10 years.  In contrast, BHVs in patients younger than 35 
years of age show a high frequency of structural defects with up to 100% 
failure, requiring re-operation in 5 years (Schoen & Levy 1999).  SVD takes the 
form of calcium nodules, leaflet tears, fractures or perforations which result in 
stenosis, leaflet immobilization and tearing (Figure 1.2).  This damage causes 
clinical pathologies due to excessive pressures (stenosis) or valvular 
regurgitation (Schoen and Levy 2005).  The mechanism(s) which contribute to 
valvular calcification and degeneration are multifactorial and include mechanical 
strain, biochemical, immunological and surgical (patient - size mismatch) 
factors. 
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Figure 1.2  Degenerated BHVs.  A) Excessive nodular calcification (arrows) on porcine 
cusps resulted in stenosis of the valve.  B) One cusp prolapsed (arrow) and a tear (arrowhead) 
resulted in valve regurgitation [as published in (Nair, Law, Li, Phillips, David, & Butany 2012)]. 
 
Evidence of mechanical factors that contribute to SVD:  Tissue fixation 
strengthens and stabilizes the overall structure of the valve, however, the 
dynamic microstructural rearrangements and normal reparative processes 
typical of native heart valves are not present in BHVs and render the valve 
susceptible to progressive mechanical fatigue (Schoen & Levy 1999).  
Consistent with this, explanted failed valves exhibit leaflet tears mostly in 
regions that receive high mechanical stress, such as points of maximal flexion 
and valvular commissures.  Calcium deposition also occurs frequently at these 
points where it may further weaken the structural integrity to promote leaflet 
tearing.  Interestingly inflammatory infiltrates are also more concentrated at 
sites of high stress suggesting that mechanical injury may expose the tissue to 
cellular infiltration and further degeneration (Zilla et al. 2008). 
Evidence of biochemical processes that contribute to SVD:  Unreacted 
glutaraldehyde used during fixation can provide free aldehyde groups that may 
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entrap calcium ions (Simionescu 2004).  Fixation can also expose cellular 
phospholipids, the polar heads of which can provide nucleation sites for 
mineralisation.  In addition accumulation of infiltrating cells can contribute to 
proteolytic degradation of collagen fibres by increasing matrix 
metalloproteinases activity (Bracher et al. 2001).  Although collagen is 
effectively crosslinked by glutaraldehyde, other extracellular matrix (ECM) 
components, elastin and glycosaminoglycans (GAGs), are not as effectively 
stabilized and may be subjected to enzymatic degradation.  As noted before, 
fixed BHVs lack live cells that would normally mediate remodelling and 
replenishment of extracellular matrix proteins.  This absence of regenerating 
potential is the eventual source of BHV degradation (Schoen & Levy 1999). 
Evidence that immunological processes contribute to SVD:  Immune 
responses to implanted heart valves have long been recognized, even for 
homograft valves.  Homograft recipients may develop sensitisation to human 
leucocyte antigens after heart valve replacement  (Hogan et al. 1996).  
Explanted failed commercial animal derived BHVs show consistent evidence of 
innate and induced inflammatory reactions.  The histopathology and immune 
staining of explanted degenerated BHVs includes inflammatory infiltrates 
consisting mostly of macrophages (Manji et al. 2015) but also including platelet 
aggregates, microthrombi, surface deposition of complement components, 
antibodies and adherence of neutrophils, T cells and B cells (Manji et al. 
2012;Nair et al. 2012).  In some cases macrophages infiltration into the valvular 
tissue has been reported and correlated with phagocytosis of collagen 
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supporting the view that macrophage derived lytic enzymes and  matrix 
metalloproteinases contribute to BHV collagen degradation (Stein et al. 1988). 
The histopathology of explanted BHVs represents the terminal stage of BHV 
degeneration associated with clinical SVD.  Since SVD develops over time it is 
difficult to distinguish if this immune inflammation is a primary cause of SVD or 
a secondary reaction to a degenerating valve.  The histologpathology of BHVs 
such that detected in BHVs retrieved from left ventricular assist devices 
(LVADs), in the absence of calcification, infection or structural deterioration, 
after only a few months of implantation, exhibit similar inflammatory processes 
(Khan et al. 2008;Moczar et al. 2000) and may be more informative of the early 
degenerative process.  An immune response to BHVs is consistent with their 
age dependent degeneration, as young adults and children have a more robust 
immune system than older people (Manji et al. 2012). 
1.3 LVAD devices- early post-implantation changes 
Insight into the early events of BHV degeneration can be gained by studying 
the histopathology of BHVs prior to clinical dysfunction.  Valves retrieved from 
LVADs, originally used for a limited time span (months) as a bridge to 
transplant, represent such an opportunity.  Early LVADS produced by Novacor 
(WorldHeart, USA) contained two porcine prosthetic heart valves to regulate 
flow from the left ventricle to the pump (inflow valve) and to regulate the flow 
from the pump to the aorta (outflow valve) (Khan et al. 2008).  BHVs were 
recovered from Novacor devices implanted for 37 to 1,293 days.  Most BHVs 
were macroscopically normal without tears, perforations or calcification, 
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however, immunohistochemical analysis showed in the inflow valves deposit of 
fibrin, adherence of macrophages and neutrophil granulocytes on the outflow 
surface of the cusps.  This histopathology grew progressively more intense over 
time.  Further analysis showed the ECM stained positive for IgG and 
complement proteins C1q and C3c.  The outflow valves exhibited similar 
findings but their structural deterioration was less rapid than the inflow valves, 
which received increased mechanical stress (Moczar et al. 2000).  A second 
study of BHVs from explanted LVADs (Novacor and HeartrMate) (7 to 567 days 
implantation) indicated that a similar inflammatory response was evident in all 
cases (Khan et al. 2008).  Macrophages were found in all inflow and outflow 
valves and the inflammatory response was more severe the longer the implant 
duration.  There was no endocarditis or calcification in any of the valves.  These 
findings suggest that an early host immune response to BHVs is present soon 
after implantation.  The inflammatory reaction precedes calcification and tissue 
failure and may be a primary injury to the BHV that eventually leads to SVD.  
The histology of this process is consistent with an antibody mediated 
inflammatory reaction where antibody bound to BHV can fix complement 
attracting neutrophils, monocytes and mast cells.  Activated macrophages may 
release proteolytic enzymes, reactive oxygen and nitrogen intermediates 
(oxidative burst) resulting in damage of the surrounding tissue.  Progression of 
this antibody mediated inflammatory process can eventually lead to collagen 
degradation and calcification and thus to premature SVD. 
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1.4 Alternative processing for improving durability of BHVs 
Changes in valve design and processing have been made to improve BHV 
durability.  These changes have taken two predominant forms, engineering 
changes to improve valve flow and ease of implantation and altered chemical 
processing to reduce calcification.  The Ionescu-Shiley bovine pericardial BHVs 
were re-engineered to align the stitches at the commissures of cusps a design 
flaw in the original version (Walley and Keon 1987).  Another redesign was the 
introduction of low profile valves.  This design reduced the protrusion of the 
stent into the left ventricular cavity for improved function of mitral valve 
prosthesis.  Early versions of low profile valves had a high frequency of 
commissural tears in the right coronary cusp resulting in excess regurgitation.  
The redesign increased mechanical stress in this area leading to accelerated 
calcification and tears (Ius et al. 1996).  As a consequence of these design 
failures computational simulations of valve function and stress and bench top 
flow devices for accelerated wear testing are routinely used for such 
biomechanical studies (Vesely 2003). 
A significant research effort has been made to improve BHV tissue 
processing with the goal to reduce calcification and improve BHV durability.  
Typically these processing methods are tested in a rodent subcutaneous 
implant model to examine overall toxicity and the rate of calcification of BHV 
material and by hemodynamic testing of valve function in juvenile sheep 
(Schoen & Levy 1999). 
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1.4.1 Animal models used for the development of improved BHVs 
The juvenile rat subcutaneous implant model is used in industry to test new 
anti-calcification treatments.  Disks of fixed bioprosthetic material that have 
undergone various processing are implanted subcutaneously in rats or 
intramuscularly in rabbits.  Tissue calcification levels are determined on the 
explants after a certain period of time using spectrophotometry or other 
chemical methods.  The rate of calcification varies depending on the intrinsic 
calcification properties of the tissue, the recipient age, with younger animals 
calcifying faster than older animals, on the recipient species and site of 
implantation (Mako et al. 1999).  In juvenile rats calcification levels reach a 
range of (80-120) μg/mg after 3-weeks, with maximal calcification (200-250 
μg/mg) after 8 weeks [reviewed by (Schoen & Levy 1999)].  This subcutaneous 
implant model offers relative ease of use and its cost is low.  However, it has its 
limitations mainly in the absence of blood contact and lack of haemodynamic 
stress.  Nevertheless this model has been a valuable tool for developing 
anticalcification methods (Simionescu 2004). 
A corollary to the subcutaneous implant model is valve replacement in 
juvenile sheep.  This is a functional model where valves are implanted into 
sheep for 90 days or longer to test haemodynamic function and calcification.  
The sheep implant model simulates heart valve implantation in humans and 
consequently is expensive and technically demanding.  BHV calcification may 
develop more slowly in this model compared with the subcutaneous model often 
requiring 3-5 months to accumulate similar levels of calcification (Schoen & 
Levy 1999). 
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1.4.2 Alternative crosslinking methods 
Glutaraldehyde fixation has been the golden standard for BHVs manufacture 
since the 1960s and remains the only commercial fixative in clinical use today.  
Glutaraldehyde fixation is not without drawbacks as it shows a propensity 
towards calcification.  Glutaraldehyde is also not an effective stabilizer of major 
components of ECM, such as elastin and GAGs which may affect tissue 
strength (Tam et al. 2015).  Several alternative fixation agents have been tested 
including dye-mediated photo fixation (Photofix), alternative crosslinking agents 
such as carbodiimide, Epoxy, Genipin, and others.  Many of these preservation 
methods have shown positive results in animal models but none have not been 
adopted for clinical use (Simionescu 2004). 
1.4.3 Anticalcification treatments 
Commercial post fixation strategies have been developed to mitigate 
calcification by blocking unreacted glutaraldehyde and extracting cellular 
phospholipids (Lentz et al. 1982;Shen et al. 2001).  Unreacted glutaraldehyde is 
quenched by reacting the free aldehyde group with primary amines (Zilla et al. 
2001).  Commonly used primary amines tested to neutralize glutaraldehyde 
include L-glutamic acid, glycine, L-lysine and diamine (Zilla et al. 2001).  Other 
quenching compounds include sodium borohydride, urazole and 
biphosphonates.  Apart from neutralizing aldehydes biphosphonates bind to 
hydroxyapatite preventing further growth of calcium crystals (Zilla et al. 2004).  
Another anti-calcification compound, 2-α-amino-oleic acid (AOA®), is a 
detergent which reacts with aldehyde groups via a Schiff base reaction.  AOA is 
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considered to covalently bind to glutaraldehyde and inhibit Ca2+ circulation in 
the tissue (Chen et al. 1994).  From these glutaraldehyde quenching treatments 
only AOA processing has been adopted for clinical BHV and is used by 
Medtronic for the manufacture of the Mosaic and Freestyle valves (Girardot et 
al. 1994). 
Cellular damage during fixation exposes phospholipids which are a major 
component of the cell membrane composed of a lipid tail and negatively 
charged polar head.  Exposure of the negatively charges head is thought to 
serve to attach free plasma calcium and thereby serve as a site for calcium 
crystal growth.  Post glutaraldehyde fixation treatment with ethanol extracts 
phospholipids and cholesterol (Vyavahare et al. 1997) and has been used in 
commercial BHVs, such as the Epic valves (St.Jude Medical, Minneapolis, MN, 
USA).  Other clinical BHVs (Medtronic, Minneapolis, MN, USA) use sodium 
dodecyl sulphate (T6), to extract lipids (Simionescu 2004).  Multiple variations of 
post fixation processing have been developed by Edwards Lifesciences 
Corporation.  XenoLogix® uses a combination of ethanol, formalin and Tween-
80 to reduce phospholipid content and calcification of tissues.  Tissues treated 
by this method show reduced calcification in the rat subcutaneous implant 
model (Shen et al. 2001).  This process is used commercially in the Carpentier-
Edwards PERIMOUNT aortic and PERIMOUNT Plus mitral valves (Edwards 
Lifesciences Corporation, Santa Ana, CA, USA).  Edwards Lifesciences have 
developed ThermaFix TissueTM which involves heat treatment of glutaraldehyde 
fixed tissue, followed by alcohol to kill bacteria and surfactant for phospholipids 
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removal.  These treatments have been used in commercial valves (e.g. Magna).  
Edwards Lifesciences is also developing additional post fixation processing to 
cap free aldehydes, extract phospholipids and infuse glycerol into the tissue to 
allow dry storage of the valves.  This ResiliaTM treatment has been reported to 
significantly reduce calcification compared to glutaraldehyde fixed tissue in the 
intramuscular rabbit model (Tod and Dove 2016), but has not yet been used in 
commercial valves. 
These anti-calcification treatments reduced calcification in the subcutaneous 
implant and juvenile sheep models (Weber et al. 2006), and have been in 
commercial use for many years but have not substantially altered BHV 
durability, nor permitted their routine use in younger patients.  This suggests 
that the calcification mechanisms addressed by these methods (free aldehydes 
and phospholipid nucleation sites), while significant have not addressed a key 
mechanism which affects age dependent SVD of BHVs in younger patients. 
1.5 Decellularized valves 
Another strategy to reduce cell related antigenicity from bioprosthetic 
materials is decellularization.  A decellularization protocol generally includes the 
use of ionic solutions or physical treatments to lyse the cell membrane, followed 
by enzymatic treatment to separate cellular components from ECM and 
detergents to remove the cellular debris (Gilbert et al. 2006).  Although 
decellularized materials are used in several clinical applications, decellularized 
valves had detrimental effects when used in children and were removed from 
the market (Simon et al. 2003).  These decellularization protocols do not seem 
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to eliminate xenoantigens from bioprosthetic tissue.  The only decellularized 
heart valve commercially available is a cryo-preserved human heart valve, 
CryoValve aortic valve (CryoLife, USA). 
1.6 Further evidence of immune injury and SVD 
The failure of anticalcification treatments to provide a BHV durable in young 
adults and children supports the notion that immunologic injury contributes to 
degeneration of BHVs.  The antibody mediated inflammatory response is 
consistent with results in subcutaneous implant models.  Vincentelli and 
associates used the juvenile sheep subcutaneous implant model to compare 
calcification of fixed pericardium (0.65% glutaraldehyde) of xenogeneic (human) 
and autologous (sheep) origin.  They showed that fixed human pericardium had 
35-fold more calcium accumulation than autologous (sheep) fixed tissue 
(Vincentelli A et al. 1998).  The above findings supported the notion that more 
immunogenic tissue (xenogeneic as opposed to autologous), despite fixation 
induces an immune response which is accompanied by proportionate 
calcification, much higher than the intrinsic calcification of autologous, less 
immunogenic tissue.  Further evidence that immune rejection is involved in 
BHVs calcification was demonstrated by Manji and colleagues using young rats 
transplanted with glutaraldehyde fixed or fresh right outflow tracts (containing 
both aortas and valve) from rats (syngeneic), or fixed right outflow tracts from 
guinea pigs (xenogeneic).  Xenogeneic implants showed three times more 
inflammation.  Graft infiltration by T cells and macrophages was ten times more 
intense compared to syngeneic implants, either glutaraldehyde fixed or fresh, 
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and there was a three-fold induction of antibody in the xenogeneic recipients not 
seen in the syngeneic groups.  Xenogeneic groups that had received steroids 
demonstrated decreased inflammation and lower antibody rise supporting the 
thesis that this is an immune mediated process.  This study revealed that 
xenogeneic fixed valves underwent cellular/ humoral rejection and calcified 
secondarily (Manji et al. 2006). 
Human and Zilla (Human and Zilla 2001) directly tested  the impact of 
antibody on tissue calcification using a subcutaneous implant model.  They 
created a specific immune response by immunizing New Zealand White rabbits 
with glutaraldehyde fixed porcine aortic wall tissue.  Glutaraldehyde fixed 
porcine aortic wall buttons incubated in either immunized serum or in pre-
immunization serum were then subcutaneously implanted and the level of tissue 
calcification determined three weeks later.  Calcification of the tissue that had 
been incubated with specific antibody was significantly higher than that of the 
tissue that had been incubated in the control pre-immune serum.  These results 
showed that specific antibody binding to fixed bioprosthetic material can 
enhance calcification (Human & Zilla 2001) and moved the authors to propose a 
model of graft-specific antibody induced tissue calcification. 
These experimental results show that there is a greater immune response to 
xenogeneic tissue, compared to autologous tissue, and that antibody bound to 
fixed bioprosthetic tissue induces increased calcification.  Since younger 
patients typically have more reactive immune systems, this immune mediated 
mechanism of BHV injury may have an important role in age-dependent SVD.  
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The major difficulty with this mechanism however is that glutaraldehyde fixation, 
through inter and intramolecular crosslinking drastically reduces the 
immunogenicity of the protein component of BHV tissue making it difficult to 
envision how such an immune response might develop in patients. 
1.7 Xenogeneic glycans and BHV immunogenicity 
Animal tissue contains carbohydrate structures not expressed in humans.  
The major xenogeneic glycan is terminal galactose-α1,3-galactose-β1,4-N-
acetylglucosamine (α-Gal).  The α-Gal trisaccharide is expressed on 
glycoproteins and glycolipids of all mammalian species except humans and Old 
World primates.  This trisaccharide is synthesized by the enzyme α1,3 
galactosyltransferase (Gal transferase) in the Golgi apparatus.  Gal transferase 
catalyses the transfer of a galactose from UDP-galactose to galactose-β1,4-N-
acetylglucosamine with an α1,3 linkage.  A similar α1,3 linkage of galactose is 
also found in the B blood group antigen, but this antigen is formed by the action 
of a distinct B-transferase and not Gal transferase.  The Gal transferase is 
encoded by GGTA-1 gene.  Pig tissues have high levels of α-Gal epitopes with 
an estimated 107 epitopes on pig endothelial cells and 1011 epitopes/mg of 
porcine ligament tissue (Stone et al. 2007).  Cows make similarly high levels of 
α-Gal.  The α-Gal antigen is widely expressed in all major porcine organs and 
on many secreted mammalian glycoproteins including thyroglobulin, fibrinogen 
and immunoglobin molecules (Thall and Galili 1990).  Α-Gal is also expressed in 
matrix proteins such as laminin (Arumugham et al. 1986), bovine collagen 
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(Langeveld et al. 1991) and heparin sulphate proteoglycans (Fujiwara et al. 
1993;Maruyama et al. 2000).  
Humans do not synthesize the α-Gal glycan because of mutations in the 
GGTA-1 gene (Joziasse et al. 1989;Larsen et al. 1990).  As a consequence 
humans, apes and Old World monkeys which do not produce α-Gal 
oligosaccharide, now produce high levels of anti-Gal antibodies.  These 
antibodies are not present at birth but develop over the first year of life 
presumably in response to stimulation by gastrointestinal microflora (Galili et al. 
1988a). Human anti-Gal antibody is present in all isotypes, (IgM, IgG, IgA, IgE) 
and is highly abundant making up approximately 1% of circulating IgG 
immunoglobulins (Galili et al. 1993).  Individual anti-Gal antibody levels can vary 
widely and the affinity of anti-Gal antibody for the α-Gal epitope is reduced on 
average 6-fold in elderly populations (70 - 96 years) (Wang et al. 1995).  Anti-
Gal antibodies are cytotoxic and form a first line of defence against infectious 
organisms, including xenogeneic enveloped viruses, bacteria and protozoa, 
which were found to express α-Gal antigen (Galili 2013). 
1.8 Anti-Gal antibody and animal tissues 
Xenotransplantation seeks to ameliorate the chronic shortage of organs for 
transplantation by developing animal organs (pig) which can be used for human 
transplantation.  When pig organs are transplanted into non-human primates 
however they are rapidly rejected by a complement mediated process, called 
hyperacute rejection (HAR).  This rejection is caused by naturally occurring anti-
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Gal antibodies which bind to α-Gal epitopes present on porcine vascular 
endothelial cells (EC).  Anti-Gal antibody binding activates the complement 
cascade resulting in EC death, a loss of vascular patency, intravascular 
haemorrhage and thrombosis with organ rejection within minutes to hours of 
transplantation.  If HAR is blocked, then porcine xenotransplantation leads to a 
strong induction of anti-Gal antibodies (McCurry et al. 1997) resulting in acute 
vascular rejection (AVR) characterized by a progressive deposition of IgG, IgM, 
edema, diffuse thrombosis, ischemic injury and cellular necrosis.  Although 
these studies utilize live animal tissues, and the detailed mechanism of graft 
rejection may not be applicable to fixed bioprosthetic tissues, these studies 
demonstrate the clear pathogenic potential of preformed human anti-Gal 
antibody even in the absence of an induced antibody response. 
To eliminate anti-Gal mediated xenograft rejection, xenotransplantation 
researchers have used nuclear cloning technology (Wilmut et al. 1997) and 
homologous recombination in somatic cells to produce pigs with a targeted 
mutation in the GGTA-1 gene (GTKO pigs) (Lai et al. 2002;Nottle et al. 
2007;Phelps et al. 2003).  By numerous criteria - anti-Gal antibody and lectin 
staining of tissue and cells, α-Gal-specific western blots of cell proteins, flow 
cytometry of GTKO pig cells (Nottle et al. 2007), biochemical analysis of GTKO 
glycolipid tissue extracts (Diswall et al. 2010) and pig-to-primate 
xenotransplantation (Kuwaki et al. 2005) - GTKO pig tissue is free of the α-Gal 
trisaccharide.  Indeed GTKO pigs have now lost tolerance to α-Gal antigen and 
like humans spontaneously make anti-Gal antibody (Fang et al. 2012).  Use of 
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GTKO organs in xenotransplantation has not eliminated xenograft rejection but 
has highlighted the role of non-Gal antigens in xenograft rejection (Byrne and 
McGregor 2012).  The most significant non-Gal antigens identified in 
xenotransplantation for BHVs are the minor xenogeneic glycans N-
glycocylneuraminic acid (Neu5Gc), a modified sialic acid not produced in 
humans and the SDa blood group like glycan produced by porcine beta-1,4 N-
acetylgalactosaminyltransferase 2, (B4GALNT2) glycosyltransferase.  Both of 
these carbohydrate antigens are immunogenic in humans although their impact 
in xenotransplantation is less than the effect of anti-Gal antibody (Park et al. 
2012). 
1.9 Bovine and porcine BHVs express α-Gal antigen 
There is strong evidence that commercial BHVs, despite fixation and 
processing, express the α-Gal antigen.  Patients implanted with BHV show a 
significant increase in anti-Gal IgM antibodies after heart valve surgery whereas 
patients treated with MHVs or undergoing coronary artery bypass graft surgery 
show no similar increase.  In adult patients the induced anti-Gal IgM antibody 
response was increased by approximately 45% (Konakci et al. 2005).  
Paediatric patients (median age 132 months, range: 14-330 months) show a 
much stronger induction of anti-Gal antibody one week after BHV implantation 
exhibiting up to 7-fold increase in IgM and a sustained 32-fold increase in IgG 
(Park et al. 2010). 
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In addition to these clinical observations our group directly compared the 
immunogenicity of commercially prepared WT and GTKO BHVs implanted in 
the mitral position in non-human primates.  The recipients that received WT 
valves showed a sustained significantly increased level of α-Gal-specific 
immune stimulation over the first post implant year which was not observed in 
the GTKO valve recipients (McGregor et al. 2013).  
Commercial bioprosthetic heart valves show positive staining for the α-Gal 
antigen using α-Gal-specific lectin (GSIB-4) or anti-Gal monoclonal antibodies.  
Accurate staining for α-Gal antigen can however be difficult unless one 
appreciates the ubiquity of this antigen in animal tissues.  For example, animal 
sera, typically used to block non-specific binding to tissue sections, are rich in α-
Gal antigen, and therefore they are inappropriate blocking agents.  Likewise the 
lectin Griffonia simplicifolia lectin I isolectin B4 (GSIB-4) binds to α-Gal 
oligosaccharide but has an absolute requirement for calcium for α-Gal-specific 
binding.  Commonly used calcium-free phosphate buffered saline is thus not 
suitable.  Accounting for these technical issues it is evident that commercial 
BHVs clearly stain with both GSIB-4 (Kasimir et al. 2005;Konakci et al. 
2005;McGregor et al. 2011;Naso et al. 2011) and anti-Gal antibodies (Naso et 
al. 2013a).  In the best controlled staining studies, using competition with free α-
Gal trisaccharide to block GSIB-4 binding and GTKO porcine tissues as 
negative controls, specific GSIB-4 binding is evident in valvular endothelial cells 
and throughout the matrix of the valve leaflet in wild type (WT), α-Gal positive 
[GT(+/+)], pig heart valves (McGregor et al. 2011).  Glutaraldehyde fixed 
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commercial devices show a similar GSIB-4 staining pattern indicating that the α-
Gal antigen remains after fixation (McGregor et al. 2011) and is still present 
even after anti-calcification treatment (Lila et al. 2010).  In addition to GSIB-4 
staining a monoclonal anti-Gal IgM antibody, M86 (Galili et al. 1998) has been 
used for staining α-Gal on commercial BHVs.  Together these findings indicate 
that despite fixation and anticalcification treatment the α-Gal epitope remains 
present at high levels in BHVs and remains immunogenic. 
The pathogenicity of human anti-Gal antibody in xenotransplantation, the 
universal presence of anti-Gal antibody in humans and the abundance of α-Gal 
on commercial BHVs suggest that anti-Gal antibody may mediate an antibody 
induced BHV immune injury, as suggested by Human and Zilla (Human & Zilla 
2001), even in the absence of an induced antibody response. 
1.10  Effects of anti-Gal antibodies on calcification 
To determine if human anti-Gal antibody can promote calcification of fixed 
bioprosthetic tissue we previously compared calcification of WT and GTKO fixed 
porcine pericardium in the presence and absence of anti-Gal antibody in both a 
rat and rabbit subcutaneous implant model.  We recently have shown that 
naturally occurring preformed human anti-Gal antibody enhances calcification of 
α-Gal-positive but not α-Gal-free tissue in both rat and rabbit subcutaneous 
implant models.  Fixed pericardium disks from WT pigs implanted 
subcutaneously into juvenile rats or rabbits had significantly higher levels of 
calcium after 3 weeks, if pre-incubated with human anti-Gal antibody (111 ± 8.4 
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µg/mg) compared to non-labelled WT pericardium (74 ± 9.6 µg/mg).  This anti-
Gal mediated effect was not present when GTKO pericardium was pre-
incubated with anti-Gal antibody.  Indeed calcification of GTKO pericardium was 
generally lower than WT tissue both in the presence or absence of anti-Gal 
antibody (55 ± 11.8 µg/mg and 51 ±9.1 µg/mg, respectively).  Labelled with anti-
Gal antibody WT pericardium had significantly higher calcification (111 ± 8.4 
µg/mg) compared to antibody labelled GTKO pericardium (55 ± 11.8 µg/mg) 
(McGregor et al. 2011).  The same effect of anti-Gal antibody was present when 
fixed tissues were further treated with formaldehyde, ethanol and Tween 80 
(FET) to reduce the lipid content and minimize calcification.  FET treatment 
reduced levels of calcification in WT pericardium from 155.7 ± 7.1 µg/mg to 4.6 
± 4.2 µg/mg.  Pre-incubation with anti-Gal antibody increased calcification of 
FET treated WT pericardium to 43.8 ± 8.5 µg/mg.  Calcification of FET treated 
GTKO pericardium (0.35 ± 0.1 µg/mg) was significantly lower than in FET 
treated WT pericardium (4.6 ± 4.2 µg/mg).  In the presence of anti-Gal antibody, 
FET treated WT pericardium calcified significantly more than FET treated GTKO 
pericardium (43.8 ± 8.5 versus 5.7 ± 2.9 µg/mg) (Lila et al. 2010).  These 
experiments showed that anti-Gal antibody accelerates calcification in 
glutaraldehyde fixed WT tissue and suggest that this inflammatory response can 
be avoided by using α-Gal-free, GTKO tissue (McGregor et al. 2011). 
1.10.1 Studies in GTKO mice 
GTKO mice do not make the α-Gal antigen and spontaneously produce low 
levels of anti-Gal IgM.  With immunization these mice also produce anti-Gal IgG 
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(Gock et al. 2000).  GTKO mice would naturally appear to be an ideal model for 
studying anti-Gal induced tissue calcification and some studies have been 
reported (Kim et al. 2015a;Kim et al. 2015b;Lee et al. 2012;Lim et al. 2013).  
When glutaraldehyde fixed bovine pericardium is implanted in GTKO or WT 
mice, tissue calcification after two months was reportedly higher in GTKO 
recipients compared to WT mice.  This is consistent with an anti-Gal mediated 
tissue calcification, however, compared to rabbit and rat subcutaneous implant 
results, where calcification levels can reach 50 – 150 µg/mg, the calcium levels 
in the explanted material from GTKO mice were not very high (0.77 µg/mg of 
tissue compared to 0.12 µg/mg in fixed but not implanted tissue) (Lee et al. 
2012).  If the GTKO mice are immunized with rabbit RBCs, to induce a strong 
anti-Gal IgG response, the level of calcification after three months in the 
immunized mice (1.5 ± 0.4 µg/mg) was significantly higher than in WT mice (0.3 
± 0.1 µg/mg), but not different from naïve GTKO mice (1.1 ± 0.2 µg/mg) (Lim et 
al. 2013).  It is difficult to know if this increase was due to higher anti-Gal 
antibody levels or an additional month of subcutaneous exposure.  Calcification 
of glutaraldehyde fixed primate pericardium (free of the α-Gal antigen) and α-
Gal-positive bovine pericardium has also been compared in GTKO mice.  In this 
instance calcification of primate pericardium (3.9 µg/mg) was significantly lower 
than bovine pericardium (9.2 µg/mg) (Kim et al. 2015b).  A fourth study 
compared calcification and immune response of fixed pericardium and valves of 
porcine and bovine origin implanted for 3 months.  The IgM response in GTKO 
mice was significantly higher at 30 days post implantation and the IgG response 
remained elevated until 60 days post implantation compared to those in WT 
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mice.  All types of implants calcified significantly more in GTKO than in WT mice 
(Kim et al. 2015a).  These studies reported a consistent elevated calcification of 
α-Gal-positive tissues in GTKO recipients compared to WT recipients, but the 
overall level of calcification is very low compared to other models.  
1.11 Assays to measure a-Gal antigen on animal cells 
Galili used a classic radioimmune assay (RIA) and serial dilutions of 
radiolabelled GSIB-4 lectin to estimate the number of α-Gal epitopes on rabbit 
red blood cells (RBC).  Melibiose was used as a glycan specific inhibitor of 
GSIB-4 to control for nonspecific lectin binding.  After incubation the cells were 
washed by centrifugation and Scatchard analysis of free and bound lectin was 
used to estimate approximately 150,000 α-Gal epitopes per rabbit erythrocyte 
(Galili et al. 1987).  This assay was initially conducted at 37 oC, where lectin 
binding might not be stable and there was some concern that the washing 
procedure might strip cells of bound lectin.  The analysis was repeated 
incubating serial dilutions of radio-labelled GSIB-4 at 4oC, for 1 hour with 
various cell types and the cells were separated from unbound lectin by banding 
in a Ficoll-Hypaque gradient.  This study estimated 10x106 α-Gal epitopes on 
porcine aortic endothelial cells and 1.2x106 epitopes on mouse SP2/0 cells 
(Galili et al. 1988b).  A second estimate of α-Gal levels on rabbit RBCs was not 
reported, so the impact of the change in incubation temperature and cell 
isolation is not obvious. 
Galili later developed an anti-Gal monoclonal antibody (M86) and used it to 
create an inhibition assay to measure α-Gal epitopes on cells (Galili et al. 1998).  
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In this assay variable numbers of cells were incubated with a standard 
concentration of M86 overnight, at 4oC, in an effort to attain equilibrium binding.  
The cells were then removed by centrifugation and the level of free M86 was 
measured by binding to a BSA-Gal conjugate in an ELISA microtiter plate.  The 
higher the level of α-Gal expression on cells, the more they bind M86 leaving 
less M86 in the supernatant for the Gal ELISA.  This creates an apparent 
inhibition of the Gal ELISA compared to M86 not incubated with cells.  Galili 
created an inhibition profile for each cell type and used the half maximal 
inhibitory concentration (IC50) derived from these profiles as an estimate 
antigen density.  The mouse myeloma SP2/0 cells (estimated to have 1.2x106 
α-Gal epitopes by the earlier GSIB-4 RIA analysis) were used as a reference 
standard.  Rabbit RBC, which showed approximately 2-fold greater inhibition in 
the Gal inhibition ELISA compared to the SP2/0 standards were estimated to 
have 2x106 α-Gal epitopes/ rRBC.  This is more then 10-fold higher than the 
original estimate determined by the RIA method.   
Galili and another group (Naso et al. 2011) have used the SP2/0 estimate of 
1.2x106 epitopes per cells as a standard multiplier for calculating α-Gal 
expression on other cells and tissues.  This is unusual since GSIB-4 and M86 
have distinctly different valency (4 vs. 10 respectively), affinity and the original 
RIA assay, performed at 4 oC for 1 hour, was not likely to be at equilibrium.   
The practice of using this extrapolation to report epitope numbers is evident 
in the literature, but for the reasons above is not likely to be accurate. 
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1.12 Summary and aims 
The presence of α-Gal antigen on commercial BHVs, the universal presence 
of anti-Gal antibody in patients, the continued immunogenicity of the α-Gal 
antigen, despite fixation and the strong induction of anti-Gal antibody in young 
patients after BHV implantation and the anti-Gal dependent calcification of fixed 
α-Gal-positive porcine pericardium suggest that anti-Gal antibody binding to α-
Gal on BHVs may initiate an antibody dependent inflammation, which leads to 
BHV degeneration.  This mechanism may significantly contribute to age-
dependent SVD.  The α-Gal-dependent immune injury can be eliminated if α-
Gal is removed from the BHV using enzymatic removal of α-Gal with α-
galactosidase (Stone et al. 2007) or using tissue from GTKO pigs.  The 
development of new low antigen BHVs lacking the α-Gal carbohydrate may 
significantly enhance BHV durability in young patients.  Development of this low 
antigen valve requires assays to monitor α-Gal levels in bioprosthetic material. 
 
Hypothesis 
My hypothesis is that antibody binding to BHVs increases their calcification 
and degeneration by augmenting an inflammatory reaction.  Natural anti-Gal 
antibody, present in recipient patients, binds to the major xenoantigen α-Gal 
expressed on BHVs and is likely to play a crucial dominant role in this process. 
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Aims of the project 
1) Quantification of α-Gal on fixed animal tissues. 
The first aim of my project was to develop an assay that would allow reliable 
quantification of α-Gal on fixed bioprosthetic materials.  I investigated two 
different approaches - a biochemical enzymatic cycling assay to detect α-Gal 
released by α-galactosidase and an inhibition ELISA assay using α-Gal specific 
lectin GSIB-4 and anti-Gal monoclonal IgM antibody M86. 
2) Measuring the effects of anti-calcification processing on α-Gal levels in 
bioprosthetic tissues. 
In order to reduce the calcification of commercial BHVs, they are processed 
with detergents and other chemical compounds, which may also affect the α-
Gal content of the devices.  The second aim of my project was to use the 
inhibition ELISA developed in “aim 1” to measure α-Gal levels on tissue 
processed with anti-calcification treatments that are applied for production of 
commercial BHVs, as well as in various commercial BHVs.  This analysis 
defined α-Gal levels associated with different processing and can be used to 
relate the clinical performance of those devices to their α-Gal content.  
3) Investigation of the effects of anti-Gal antibody binding on fixed tissue 
calcification in vivo. 
The final aim of my project was to determine using an in vivo model whether 
anti-Gal antibody binding increases calcification of fixed BHV tissue depending 
on its α-Gal content.  This aim was investigated using fixed WT and GTKO pig 
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pericardium implanted subcutaneously in GTKO mice.  GTKO mice lack α1,3GT 
enzyme (GGTA-1 gene) and therefore do not express α-Gal, but make anti-Gal 
antibody.  These experiments compared the effects of anti-Gal antibody on 
calcification of WT and GTKO BHV tissues in a host animal (GTKO mice) which 
makes anti-Gal antibody. 
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2 Materials and Methods 
All chemicals unless noted were purchased from Sigma-Aldrich, UK. 
2.1 Introduction to Methodology 
Glutaraldehyde fixed pig pericardium is currently used in clinical BHVs 
(Medtronic, CoreValve) and was used in these studies as a model bioprosthetic 
tissue.  
Antigen levels on cells are commonly measured by flow cytometry where 
quantitative estimates of antigen levels are made on a per cell basis.  Tissue, 
consisting of a mixture of cell types and a collection of extracellular matrix 
components is more complex and not readily assessed by flow cytometry.  
Therefore, additional methods are needed to measure α-Gal on fixed animal 
tissue.  Two different approaches were examined.   
The first, detailed in section 2.2, estimates tissue α-Gal levels by detecting 
the amount of galactose released from the tissue after treating with α-
galactosidase.  In this approach the liberated galactose was quantified by 
reacting with galactose dehydrogenase to produce NADH which was quantified 
with a sensitive colorimetric enzymatic cycling system.  The second approach, 
detailed in section 2.5, was developing an α-Gal inhibition ELISA assay (GIE) 
using the α-Gal-specific lectin GSIB-4 or a commercially available mouse anti-
Gal monoclonal IgM antibody M86.  The GIE assay was very effective and was 
the main analytical method used to quantify α-Gal levels on pig pericardium. 
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Throughout this research glutaraldehyde fixed porcine pericardium was used 
as a model bioprosthetic tissue.  The fixation method is detailed in section 2.10.  
Also in that section are described the anticalcification extraction methods.  
These extraction processes model the commercial process commonly used for 
clinical BHVs.  Our interest was to determine, using the GIE, if the 
anticalcification effect of these extraction methods eliminates α-Gal.  
Subcutaneous implantation of fixed pericardium in GTKO mice (2.12.3) is the 
method used to investigate the role of anti-Gal antibody to promote tissue 
calcification.  Subcutaneous implantation in rodents or rabbits is a standard 
method used to assess the propensity of tissue to calcify, but in this instance we 
use the GTKO mouse line which spontaneously makes anti-Gal antibody.  The 
remaining methods are standard procedures used to detect anti-Gal antibody 
(α-Gal ELISA section 2.6), genotype GTKO mice (PCR genotyping section 
2.11), characterize anti-Gal reagents and the sensitivity of the GIE (flow 
cytometry section 2.7) and detect tissue calcification (section 2.13). 
2.2 Enzymatic detection of a-Gal antigen 
 
Enzymatic detection of α-linked galactose was adopted from commercial 
methods to detect lactose (Essig and Kleyn 1983;Huber et al. 1975).  The assay 
was based on the following strategy.  Coffee bean α-galactosidase, specifically 
cleaves galactose in α 1,3 glycosidic bond, was used to release galactose from 
α-Gal containing tissue (Luo et al. 1999).  Galactose was subsequently reacted 
with galactose dehydrogenase (GH) and nicotinamide adenine dinucleotide 
(NAD), to yield a stoichiometric production of reduced NAD (NADH) and D-
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galactono-1,4-lactone (Figure 2.1).  The initial detection method was to monitor 
production of NADH by measuring its absorbance at 340 nm using a NanoDrop 
2000 spectrophotometer (ThermoScientific, UK). 
 
 
 
 
To calibrate this detection method galactose solutions from 0.039 mM to 10 
mM were incubated in 200 µl reactions with 5 µg/ml β-galactose dehydrogenase 
from Pseudomonas fluorescens (Sigma-Aldrich, UK) in a reaction buffer 
containing 1 mM NAD, 20 mM trisaminomethane (Tris) and 150 mM NaCl, pH 
8.6, at 25 oC for 1 hour.   
For enhanced detection of NADH a commercially available NAD+/NADH 
colorimetric assay (CycLex, MBL, UK) was used.  The CycLex system, based 
on enzymatic cycling, is an amplifier which couples the reactions of alcohol 
dehydrogenase (ADH) and diapharase, to continuously cycle the conversion of 
NADH into NAD and back (Figure 2.2).  Linked to this is the NADH dependent 
formation of a coloured, water soluble formazan terazolium salt (WST-1), which 
is measured by absorbance at 450nm.  The enzymatic amplification process 
starts by addition of NADH or NAD and results in a proportionate formation of 
WST-1-formazan. 
 
Figure 2.1  Reaction of galactose with galactose dehydrogenase in the presence of NAD
+
 
forms NADH and D-galactono-1.4-lactone. 
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Elimination of NAD and NADH 
Because the CycLex enzymatic cycling system is activated by the addition of 
either NADH or NAD, these components, must be eliminated from the tissue 
(present at low levels).  The high levels of NAD during the GH reaction (Figure 
2.1) must also be eliminated prior to the cycling reaction.  NAD and NADH were 
depleted as described in (LOWRY et al. 1961).  NAD was eliminated using 0.05 
M NaOH, pH 10 and heating at 60 oC in thermoblock (Analog Heatblock, VWR) 
for 1 hour.  After alkali heat treatment the samples were left to cool to room 
temperature (RT) and were neutralized by addition of HCl to 0.05 N and put on 
ice for 5 minutes (min).  NADH was eliminated with 0.05 M HCl, pH 4, at 60 oC, 
for 1 hour.  Prior to cycling enzyme reaction samples were centrifuged at 14,000 
rpm (Microfuge 16 Centrifuge, Beckman Coulter, UK) for 5 min to remove the 
precipitating salts and supernatants were transferred into a 96-well microplate 
(Nunc, UK).  To 25 µl of each sample 75 µl of cycling enzyme reaction mix was 
added with the final reaction mix containing 6% ethanol, 100 mM Tris pH 8.6, 59 
µg/ml ADH, 100 µM WST-1, 100 µg/ml diaphorase.  Samples were left to react 
in the dark at RT for 1 hour.  The amount of formazan was measured by 
absorbance at 450 nm using a microplate reader (BioTek, ELx808) and Gen5 
1.11 software.  A standard curve of serially diluted NADH (15.6 nM – 1000 nM) 
was measured in parallel. 
The overall strategy for this enzymatic detection of α-Gal antigen is depicted 
in (Figure 2.2). 
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Figure 2.2  Enzymatic detection of galactose.  NAD and NADH in the tissue were depleted 
by acidification at pH 4, or alkalisation at pH 10, respectively, with heating at 60 
o
C.  Tissue was 
digested with α-galactosidase to release galactose.  Galactose was reacted with galactose 
dehydrogenase to produce stoichiometric amount of NADH.  NAD from this reaction was 
depleted by addition of NaOH until pH=10 and heating at 60 
o
C.  Samples were neutralized with 
HCl and subsequently mixed with the cycling enzyme system reaction mix.  A coloured WST-1 
formazan was produced and measured at 450 nm.  NADH standards were used to calibrate 
galactose content. 
 
2.3 Cell culture 
Primary α-Gal positive porcine aortic endothelial cells (PAECs) and a 
transformed α-Gal-free (GTKO) PAEC cell line (15502) with a disruption of the 
GGTA-1 galactosyltransferase gene (Azimzadeh et al. 2014) were used.  Cells 
were cultured in endothelial cell basal medium-2 (EBM-2) supplemented as 
indicated by the manufacturer with 10 ml fetal bovine serum (FBS), 0.5 ml 
human recombinant vascular endothelial growth factor (VEGF), 0.5 ml ascorbic 
acid, 0.2 ml hydrocortisone, 0.5 ml gentamycin sulphate (GA-1000), 2 ml 
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recombinant human fibroblast growth factor (rhFGF-B), 0.5 ml recombinant 
human epidermal growth factor (rhEGF), 0.5 ml recombinant long R insulin-like 
growth factor 1 (R3-IGF-1) and 0.5 ml heparin (Lonza, UK).  Cells were cultured 
in 75 cm2 polystyrene flasks (Corning, The Netherlands) in a 37oC, 5% CO2 and 
95% humidified incubator.  Cells were expanded when they reached 70-80% 
confluency by washing with phosphate-buffered saline (PBS) [155.17 mM 
sodium chloride (NaCl), 1.06 mM potassium phosphate monobasic (KH2PO4), 
2.97 mM sodium phosphate dibasic (Na2HPO4-7H2O)], pH 7.4 (Gibco, UK), 
followed by a trypsin digest (TrypLE Express, Gibco) at 37 oC, for 1 - 2 minutes, 
to detach the cells from the plate.  Cells were resuspended in 10 ml media by 
repeated pipetting and transferred to a 50 ml centrifuge tube.  To determine the 
cell number an aliquot of cells was mixed 1:1 with trypan blue solution (Sigma-
Aldrich, UK) and the number of live cells, which exclude the trypan blue dye, 
were counted in a haemocytometer.  For continued cell growth the cells were 
split 1:3 and fed with new culture media at 2 day intervals.  Primary PAECs 
were not cultured beyond the 6th passage.  
2.4 Production and purification of anti-Gal hybridoma antibody  
Anti-Gal IgG-secreting hybridomas GT5 (Xu et al. 2003) were cultured in 
protein-free medium RPMI 1640 + GlutaMAX –I (Gibco) in a humidified 5% CO2 
incubator at 37 oC.  Approximately 1 litre of exhausted hybridoma supernatant 
was produced using 3-layer multi-flasks (TripleFlasks, Nunc, UK).  
Supernatants were collected and equal volume of filtered (0.2 μm vacuum 
filtration system, VWR, UK) saturated ammonium sulphate was added drop 
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wise at 4oC under constant stirring.  The mixture was kept at 4 oC overnight to 
precipitate.  The precipitated proteins were centrifuged at 18,000 rpm in a 
Sorvall centrifuge, at 4 oC for 30 min and re-suspended in approximately 1.5 ml 
sterile PBS.  Samples were dialysed (SnakeSkin pleated dialysis tubing, 
Thermo Scientific, UK) against PBS at 4oC under constant stirring for 4 hours 
after which the PBS was replaced and dialysis continued at 4 oC overnight.  The 
purity of the precipitated anti-Gal antibody was measured by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the protein 
concentration was determined by absorbance at 280 nm using a Nanodrop 
spectrophotometer. 
2.5 Α-Gal Inhibition ELISA (GIE) 
An α-Gal-specific inhibition enzyme linked immunosorbent assay (ELISA) 
was used to quantify the amount of α-Gal present in fixed α-Gal-positive and 
GTKO pig cells and pericardium.  This assay which was adapted from the 
method developed by Galili (Galili et al. 1998) consisted of two stages.  In the 
first stage α-Gal containing oligosaccharides, tissues or cells were incubated 
with an anti-Gal reagent.  For our analysis we tested three reagents, 
biotinylated Griffonia simplicifolia lectin I isolectiin B4 (GSIB-4) (Vector 
laboratories, UK) and anti-Gal IgM hybridomas M86 (Enzo life sciences, UK) 
and anti-Gal IgG hybridoma GT5 (Xu et al. 2003).  During this incubation a 
portion of the anti-Gal reagent is complexed with α-Gal antigen.  In the second 
stage a Gal ELISA was used to measure the level of free α-Gal binding reagent.  
The apparent inhibition due to binding of the anti-Gal reagent and α-Gal 
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antigen, compared to the anti-Gal reagent alone was used to estimate the 
amount of α-Gal in the sample. 
Stage 1: Gal Inhibition 
PAECs (0.5 up to 7.5x106 cells), glutaraldehyde fixed (0.6%) 3 mm diameter 
disks (4 or 8 disks per sample) of porcine pericardium, or monomeric α-Gal 
trisaccharide (30 µM – 7500 µM) were incubated at 4 oC, overnight or for two 
days, with either 150 µl of a 1:10 dilution of M86 supernatant, or biotinylated 
GSIB-4 (0.125 µg/ml) in microcentrifuge tubes (Elkay, UK).  The M86 and GSIB-
4 were diluted in 1% bovine serum albumin (BSA) in 50 mM Tris, 150 mM NaCl, 
10 mM CaCl2, 10 mM MgSO4, pH 7.4.  After primary incubation tissue or cells 
were removed by centrifugation at 1500 rpm, at 4 oC, for 10 min in a 
refrigerated centrifuge (Microfuge 22R Centrifuge, Beckman Coulter, UK).  
Supernatants were transferred into clean microcentrifuge tubes and were 
further centrifuged at 13,500 rpm at 4 oC for 30 min.  The final supernatants 
were tested by Gal ELISA.  For each experiment a minimum of 3 samples (cells 
or pericardium) were tested for each condition and at least 3 independent 
replicate experiments were performed. 
Stage 2: Gal ELISA 
Microtiter plates (Nunc, Thermo Scientific, UK) were coated with 50 µl of 
BSA-Gal (10 µg/ml, Vector Laboratories, UK) in carbonate buffer (15 mM 
Na2CO3, 35 mM NaHCO3 and 2 mM NaN3, pH 9.6), at 4 
oC, overnight.  Coating 
solutions were aspirated and the plate was blocked with 200 µl of 1% BSA in 50 
mM Tris, 150 mM NaCl, 10 mM CaCl2, 10 mM MgSO4 and 0.1% Tween 20, pH 
7.4, at RT for 1 hour. 
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Samples (50 µl) were incubated in duplicate at 4 oC for 90 minutes after 
which the plate was washed 5 times with 0.1% Tween 20 PBS in an ELx50 
microplate washer (BioTek, UK).  For detection of biotin conjugated GSIB-4 50 
ul of ExtrAvidin-Peroxidase (Sigma-Aldrich) 1:1000 was added to each well and 
incubated at RT for 1 hour.  For detection of M86 (IgM) or GT5 (IgG) the plates 
were incubated with a biotin conjugated goat anti-mouse IgM (Sigma, UK) or 
IgG (Sigma, UK), diluted 1:1000 or 1:5000 respectively, at RT for 1 hour, 
washed and then incubated with ExtrAvidin-Peroxidase as previously described.  
After incubation with ExtrAvidin-Peroxidase the plates were washed 5 times and 
anti-Gal binding was visualised by addition of TMB (3,3’,5, 5’- 
tetramethylbenzidine liquid substrate, T4444, Sigma) in darkness at RT for 2 
min.  The reaction was stopped by addition of 0.5 M sulfuric acid (100 µl/ well) 
and the plate absorbance was read at 450 nm in an ELx808 microplate reader 
(BioTex, UK). 
The α-Gal content was estimated by the Gal Inhibition ELISA (GIE) by 
comparing anti-Gal reactivity after primary incubation with cells or tissues to Gal 
reactivity of the reagent alone.  This was expressed as the percentage of 
inhibition calculated by the following equation: 
Equation A 
% Inhibition = ((OD reagent – OD sample) / OD reagent) x 100 
 
“OD reagent” was the optical density measured with the anti-Gal reagent alone.  
“OD sample” was the optical density measured after incubation with α-Gal 
trisaccharide, cells or pericardium disks. 
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To compare GIE results in assays using GSIB-4 (GIEGSIB4) and M86 (GIEM86) 
the GIE was performed with increasing amounts of free monomeric α-Gal 
trisaccharide (tri-α-Gal).  The tri-α-Gal oligosaccharide is galactose-α1,3–
galactose-β1,4-GlcNAc with a hexanoic acid spacer, containing five methylene 
groups and a carboxylic acid (Byrne et al. 2002).  The inhibition curves were 
fitted as four parameter logistic curves using SigmaPlot software and the 50% 
inhibition level (IC50) was calculated.  This reference analysis allowed us to 
correlate the number of cells, or amount of tissue which produced an equivalent 
amount of inhibition compared to tri-α-Gal.  A flow diagram of the process is 
presented in (Figure 2.3). 
 
 
 
 Figure 2.3  α-Gal Inhibition ELISA (GIE) for quantification of α-Gal on tissue or 
cells.  Fixed pig pericardium disks (3 mm) or cells were incubated with anti-Gal 
reagent at 4 
o
C until equilibrium was reached.  Disks or cells were removed by 
centrifugation and the remaining free anti-Gal reactivity in the supernatants was 
measured by Gal ELISA using BSA-Gal as a solid phase antigen. 
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2.6 Detection of mouse anti-Gal IgM and IgG 
Microtiter plates were coated as described in paragraph 2.5 with BSA-Gal 
using 50 µl of (10 – 30) µg/ml BSA-Gal in carbonate buffer.  Mouse serum 
dilutions were made in 1% BSA, PBS, containing 0.1% Tween 20.  For anti-Gal 
IgMs dilutions of 1:8 to 1:128 generally covered the linear range of the assay.  
Background reactivity for anti-Gal IgM was defined by binding to BSA coated 
wells.  For the primary incubation 50 µl of each dilution was tested in duplicates 
for binding to BSA-Gal and one well for biding to BSA. 
To detect mouse anti-Gal IgG a serial titration (dilutions 1:16 to 1:4096) was 
performed to determine the dilutions within the linear range of the assay.  
Mouse IgG often showed a high background so an additional negative control, 
other than binding to BSA, was used to define Gal specific reactivity.  In addition 
to the standard serum dilutions a parallel dilution series was prepared using 1% 
BSA, PBS, 0.1% Tween 20 containing 10 mM tri-α-Gal monomer to specifically 
block anti-Gal reactivity.  Mouse anti-Gal specific IgG reactivity was calculated 
by the equation: 
Equation B 
Mouse anti-Gal IgG = (ODBSA-Gal) – (ODBSA-Gal + tri-α-Gal) 
 
The mouse Gal ELISA plates were incubated at 4 oC for 90 minutes with the 
primary serum dilutions, washed in a microplate washer 5 times in PBS, 0.1% 
Tween 20, re-blocked for 30 minutes with 200 µl per well of 1%BSA, PBS, 0.1% 
Tween 20 at RT and antibody binding detected using 50 µl of HRP-conjugated 
goat anti-mouse IgG (Pierce, Thermo Scientific, UK), or IgM (Life Technologies, 
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UK) each at 1:2000 dilution.  Secondary antibodies were incubated for 60 
minutes at room temperature after which the plates were washed and incubated 
with 100 µl of pre-warmed TMB at room temperature for 4 - 5 minutes in 
darkness.  The reaction was stopped with addition of 100 µl per well of 0.5 M 
sulfuric acid.  Data was collected by reading the plate in a plate reader at 450 
nm. 
All ELISA plates contained a dilution series of GT5 (IgG) or M86 (IgM) as 
internal standards to normalize for day to day and plate to plate variation.  The 
serum optical density data, for a minimum of 4 serum dilutions, was used to 
calculate a serum anti-Gal titre based on the serum dilution required to attain an 
OD of 1.0 (IgG) and 0.5 (IgM).  This titre was expressed after normalizing to the 
dilution of GT5 or M86, required to attain an OD of 1.0 or 0.5, according to the 
equation: 
Equation C 
Serum IgM titre = titre anti-Gal IgM(0.5) / titre M86(0.5) 
Serum IgG titre = titre anti-Gal IgG(1.0) / titre GT5(1.0) 
 
2.7 Flow Cytometry 
Binding of anti-Gal IgG (GT5 hybridoma), IgM (M86 hybridoma) or lectin 
GSIB-4 to α-Gal-positive and GTKO PAECs was determined by flow cytometry 
analysis (fluorescence-activated cell sorting: FACS) using a FACS Calibur 
(Becton Dickinson, UK).  PAECs (2x105 per assay tube) were resuspended in 
FACS buffer (1% BSA in PBS) and incubated with GT5, M86 supernatant, or 
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GSIB-4 (5 µg/ml) diluted in D-PBS (Gibco, UK), on ice for 60 min.  The cells 
were washed in 3 ml of PBS by centrifugation and resuspended in 100 µl of 
phycoerythrin (PE)-conjugated goat anti-mouse IgG (Invitrogen, UK), 
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse IgM (BD 
Pharmigen, UK), or PE-conjugated streptavidin (Anaspec, Cambridge) 
respectively and incubated in darkness, on ice, for 45 min.  Cells were 
subsequently washed and resuspended in 500 µl 1% paraformaldehyde PBS 
prior to analysis. 
2.8 Alpha-galactosidase digestion of cells 
Primary α-Gal positive PAECs and the α-Gal-free 15502 cell line were 
cultured as described in 2.3.  Cells were harvested and rinsed in PBS and 
transferred in microcentrifuge tubes at 1.5 x 106 cells/sample (100 µl).  Cells 
were incubated with Green coffee bean alpha-galactosidase (Sigma-Aldrich, 
UK) in a phosphate-citrate saline buffer (0.2 M dibasic sodium phosphate, 0.1 M 
citric acid, 0.15 M sodium chloride, pH= 6) at concentrations (2 – 10) units/ml, at 
room temperature, for 1 hour.  Cells were washed twice by centrifugation using 
PBS to remove the enzyme and subsequently used for GIE as described in 
(2.5), or stained for FACS analysis (2.7). 
2.9 Alpha-galactosidase digestion of fixed pig pericardium and 
valves 
Glutaraldehyde fixed porcine pericardium or heart valve leaflets (8 disks per 
sample) were incubated with green coffee bean α-galactosidase (2–10 units/ml) 
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in phosphate-citrate saline buffer (consistency described in 2.8) at RT, 
overnight.  Samples were washed in PBS and used in the GIEGSIB4. 
2.10 Anticalcification treatments of glutaraldehyde fixed porcine 
tissue 
Glutaraldehyde fixation: Porcine pericardium was freed from adherent fat, 
rinsed three times in big volumes of PBS and placed in 0.6% glutaraldehyde in 
20 mM HEPES, 130 mM MgCl2-6H2O, 150 mM NaCl for 24 hours, at RT.  Then 
it was placed in 0.2% glutaraldehyde and kept at 4oC. 
Different anticalcification treatments used in the production of commercial 
BHVs were used to treat glutaraldehyde fixed porcine tissue to determine their 
impact on α-Gal levels.  Before each treatment pericardium was rinsed in PBS. 
Glycine is used to cap free aldehyde groups that remain after 
glutaraldehyde fixation.  The protocol was performed as described in (Lee et al. 
2012): 
Glutaraldehyde fixed porcine tissues were incubated in 0.2 M glycine in 
PBS, pH 7.4, at 37 oC, for 2 days.  The tissues were subsequently rinsed twice 
in PBS (30 min each) and incubated with 0.1 M sodium borohydride (NaBH4) at 
room temperature, overnight.  After NaHB4 reduction the disks were washed 
twice in PBS (30 min each wash) and stored in PBS with 0.05% NaN3, 4 
oC. 
Ethanol is used to extract phospholipids.  The protocol was applied as in 
describe in (Vyavahare et al. 1997): 
Glutaraldehyde fixed tissues were placed in 80% ethanol prepared in 50 mM 
HEPES buffer, pH 7.4, at room temperature, for 24 hrs.  Subsequently the 
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tissue was rinsed in 0.9% NaCl at room temperature, for 24 hrs and stored in 
PBS with 0.05% NaN3, 4 
oC. 
FET treatment consists of treating the tissue with formaldehyde, ethanol and 
Tween 80 to remove phospholipids (Shen et al. 2001): 
Glutaraldehyde fixed porcine pericardium or valve leaflets were placed in a 
buffer containing 4% formaldehyde, in 20 mM HEPES, 13 mM MgCl2-6H2O, 
22% ethanol and 1.2% Tween 80 at 37 oC, for 6 hrs.  Subsequently tissue was 
extensively rinsed in PBS and finally stored in PBS- NaN3 0.05%, 4 
oC. 
SDS is a detergent used to extract phospholipids from the tissue: 
Glutaraldehyde fixed porcine pericardium or valve leaflets were placed in 1% 
SDS in 6 mM HEPES buffer, pH 7.4, at room temperature, for 8 hrs.  The SDS 
buffer was replaced with fresh and left at RT, overnight.  The tissue was 
extensively rinsed in PBS and finally stored in PBS- NaN3 0.05%, 4 
oC. 
Prior to the inhibition assay tissue was blocked in 1% BSA-DPBS containing 
0.1% Tween 20 and 0.05% NaN3 for GSIB-4 staining or in 1% BSA-PBS 
containing 0.1% Tween 20 and 0.05% NaN3 for M86 staining, overnight, 4 
oC. 
2.11 Genotyping of mice 
2.11.1 DNA extraction 
Balb/c mice (Line 9260, C-Ggta-1tm1, Taconic Labs, Germantown New York, 
USA) with a mutation in the α-galactosytransferase gene GGTA-1 (GTKO mice) 
were genotyped by polymerase chain reaction (PCR).  Frozen ear biopsies in 
eppendorf tubes were digested with 200 µl of proteinase K lysis buffer [5 mM 
ethylenediaminetetraacetic acid (EDTA), 200 mM NaCl, 0.2% sodium dodecyl 
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sulfate (SDS), 100 mM Tris-HCl (pH 8.5) and 1/100 volume of a 10 mg/ml 
proteinase K stock solution] in a heat block at 55 oC, with occasional vortexing 
and left overnight.  Proteinase K digests were inactivated by incubation at 80 oC 
for 15 minutes then extracted with an equal volume of phenol - chrloroform (1:1) 
by vigorous vortexing for 1 min.  Samples were centrifuged at 14,000 rpm for 5 
min and the upper aqueous phase containing the DNA was collected, carefully 
avoiding the protein interface, and transferred to clean tubes.  The phenol-
chloroform extraction was repeated once more and the DNA was precipitated 
by addition of 300 µl isopropanol.  The DNA was pelleted by centrifugation at 
14,000 rpm for 10 min.  The supernatant was discarded by inverting the tubes 
and 700 µl of 70% ethanol was added to wash out residual salts.  The DNA was 
centrifuged at 14,000 rpm for 5 min, the supernatant was discarded by inversion 
and the pellet was dissolved overnight in 50 μl of distilled water (dH2O). 
2.11.2 DNA Quantitation by spectrophotometry  
DNA dilutions (1:5) were prepared in distilled water (dH2O) and the 
absorbance of 2 μl samples were measured using a NanoDrop 
spectrophotometer at 260 and 280 nm.  Distilled water was used as a blank. 
2.11.3 PCR reactions 
Three primers were used to identify the neomycin disrupted GGTA-1 gene, 
mGTKOFwd (5’-GCACCTGAACCCTCTACATTCCTTAC-3’), mGTKORv (5’-
AGGTTGAGAATGTGAGTAGGCGTTCC-3’) and pgkNeo (5’-
ACTTGTGTAGCGCCAAGTGC-3’), (Eurofins Genomics, Ebersberg, Germany).  
The mGTKOFwd primer binds to GGTA-1 exon 9 upstream of the PGK-neo 
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insertion site and the mGTKORv primer anneals to GGTA-1 exon 9 downstream 
of the PGK-neo insertion site.  In the absence of a PGK-neo insert these 
primers amplify a 358 bp product.  When exon 9 is disrupted by a PGK-neo 
insert this primer combination does not produce a PCR product because the 
length of the product is too long (~ 1600 bp) for the extension time (30 
seconds).  The pgkNeo primer is a reverse primer which anneals to the 5’ 
portion of the PGK-neo insert.  This primer with mGTKOFwd primer produce a 
235 bp PCR product only when there is a PGK-neo insertion in exon 9 of 
GGTA-1 (Figure 2.4). 
 
 
Figure 2.4  Targeting of GGTA-1 locus (GT transferase gene) in mice. 
 
 
Each PCR reaction was prepared using 200 ng of mouse genomic DNA, all 
three primers and GoTaq G2 Green Master Mix, (Promega, Madison WI, USA) 
according to the following table using an automated Mastercycler personal 
(Eppendorf by Thermo Fisher Scientific): 
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PCR reaction  
 (μl) 
Primer GTKO Fw 1 (25 µM) 
Primer GTKO Rv 1 (20 µM) 
Primer GTKO Neo 1 (25 µM) 
Distilled Water 12 
DNA 10 (200 ng) 
2x Green GoTaq 
buffer 25 
 
The PCR cycling program consisted of an initial denaturation at 95 oC for 2 
min, followed by 30 cycles of denaturation at 95 oC for 30 seconds, annealing at 
60 oC for 30 seconds, elongation at 72 oC for 30 seconds.  After the last cycle 
there was an extended elongation at 72 oC for 5 minutes followed by a cooling 
to 6 oC. 
2.11.4 DNA gel electrophoresis 
The PCR products were analysed by electrophoresis in a 2% agarose gel 
using TBE buffer (89 mM Tris, 89 mM Boric acid, 2 mM EDTA) containing 10 
µg/mL of ethidium bromide.  PCR products were loaded into a submerged well 
along with control samples representing WT, HET and GTKO mice and DNA 
molecular weight markers, DNA 100 bp ladder (Promega, Madison WI, USA).  
All samples were mixed with loading buffer (10x buffer was 30% glycerol and 
0.2% orange G in water) prior to loading on the gel.  The gel was 
electrophoresed at 75 volts until the dye front reached 4 cm from the end of the 
gel.  DNA bands separated in the gel were viewed and recorded under 
ultraviolet light using the BioDoc-ItTM Imaging System Benchtop 3UV 
Transilluminator (UVP, Analytik Jena, Germany). 
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2.12 Animal experiments 
2.12.1 Ethical approval and Home Office licence 
Tissue calcification is a multifactorial process.  This study focuses on the 
contribution of an immune reaction to this process and therefore animal 
experiments were required to study the systemic effect of anti-Gal antibody and 
α-Gal interaction.   
Ethical approval for the animal experiments was received from the Home 
Office (United Kingdom), [Project Licence (PPL) Number: 70/7825] in 
accordance with the Animals (Scientific Procedures) Act 1986.  I received my 
personal licence (PIL) (Number: I2C8F8704) after completing Modular Courses 
(modules 1 – 4) for Home Office Licence Applicants provided by the Royal 
Veterinary College.  
Animal housing and experiments took place at the Cruciform UCL Biological 
Services Unit and were planned and performed according to the 3Rs principles.  
Throughout the experiments, care was taken to ensure the wellbeing of the 
animals. 
2.12.2 Establishment of mice colony 
Heterozygous GTKO line 9260 C-Ggta1tm1 mice were imported from Taconic 
Farms, Germantown, NY, USA and re-derived at the UCL Institute of Child 
Health Transgenic Services unit.  The offspring were screened and found 
heterozygous for the α-galactosyltransfarase gene as expected.  Re-derived 
mice were transferred to the Cruciform Animal facility where they were 
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maintained. Re-derived heterozygous individuals were crossed to produce 
homozygous GGTA-1 knockout offspring which were kept to establish a double 
knockout (GTKO) breeding colony for our experiments. 
2.12.3 Subcutaneous implantation 
Forty-day-old Balb/c GTKO mice (male and female) received subcutaneous 
implants of sterile glutaraldehyde fixed pig pericardium disks.  Disks (6.0 mm) 
were cut from sheets of glutaraldehyde-fixed WT (expressing the α-Gal antigen) 
or GTKO pig pericardium using a punch biopsy (World Precision 
Instruments,Inc., Sarasota, USA), rinsed in sterile PBS and blocked in sterile 
1%BSA- PBS.  Some of the disks were labelled with M86 supernatant diluted 
1:10 in a mixture of anti-Gal IgG GT5/GT6 (1:1) supernatants, at 4oC, for 1 
hour, rinsed in sterile saline and kept on ice until transferred to the animal unit 
for implantation.  The antibody labelling of the disks had to be completed not 
earlier than 30 min prior to implantation. 
Recipients were initially anaesthetized with 2.5% isoflurane in an induction 
chamber.  Anaesthesia was maintained using a facial mask with a flow of (1.0 - 
12.5) % isoflurane.  The implant site on the dorsal surface was shaved and 
cleansed with the antiseptic “Hibitane scrub”, (Chlorhexidine Gluconate 4% 
w/v).  Two incisions were made along the dorsal surface, one per side and a 
“pocket” was formed under the skin using forceps.  One disk was inserted in 
each pocket and smoothly placed against the body musculature, making sure it 
was flat and not folded.  The incisions were closed with 2 - 3 sutures (Mersilk, 3-
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0, RB-1, 17 mm, 1/2C, round bodied).  The animals were placed in a recovery 
chamber (37 oC) and were monitored until fully recovered from anaesthesia. 
Recipient mice (N = 10) received the following types of glutaraldehyde fixed 
implants: 
 WT pericardium,  
 WT pericardium pre-incubated with a mixture of anti-Gal IgM M86 and 
IgG GT5/GT6 antibodies (positive control), 
 GTKO pericardium  
 GTKO pericardium pre-incubated with a mixture of anti-Gal IgM M86 and 
IgG antibodies (negative control). 
Age matched mice that did not receive any implants were kept in parallel to 
provide control serum for each time point.   
Each group was composed of approximately 10 animals with 2 implanted 
disks each.  This sample size was selected based on a variance (estimated 
from a review of the literature) in mean calcification levels of ± 25% and should 
be sufficient to detect with 90% confidence a 20% change in the average level 
of calcification between samples (Anon 2013a;Anon 2013b).  
2.12.4 Blood sampling and implants retrieval 
Implants were maintained for 60, 90, and 120 days after which the animals 
were euthanized by terminal anaesthesia (5% isoflurane) followed by cerebral 
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dislocation.  The implants were recovered and blood was collected via cardiac 
puncture. 
Blood samples were left to clot at room temperature and the serum was 
recovered after centrifugation at 1500 rpm for 10 min in a refrigerated centrifuge 
(Microfuge 22R Centrifuge, Beckman Coulter, UK).  Serum was transferred to 
clean microcentrifuge tubes and further centrifuged at full speed (14,000 rpm for 
20 min) to clarify.  The final serum samples were stored at – 80 oC until 
analysed. 
Implanted disks were removed starting with an incision behind the animal’s 
neck and pulling the skin down until the implanted disks were exposed (Figure 
2.5).  The disks were carefully retrieved from the skin, while retaining whatever 
encapsulating layer.  Disks were then placed in microcentrifuge tubes with cold, 
sterile saline and briefly kept on ice until further processed for histology and 
calcium analysis. 
Approximately 1/8th sized samples of each disk was cut with a scalpel and 
placed in formalin for histological analysis.  The remaining portion was cleaned 
of the surrounding encapsulating layer, placed in an empty microcentrifuge tube 
and kept at – 80 oC, until calcium determination. 
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Figure 2.5  Retrieval of implanted disks.  An incision behind the animal’s neck was made and 
the skin was removed to expose the implanted disks.  Arrows point at the implanted disks. 
 
2.12.5 KLH-Gal conjugation 
Conjugation of α-Gal with keyhole limpet hemocyanin (KLH) to form KLH-
Gal was performed using the Imject EDC carrier protein spin kit (Thermo 
scientific, UK) using the methods described by the manufacturer.  In brief, a 
total of 4 mg KLH was conjugated to 24 mg of tri-α-Gal sugar in 0.1 M 2-[N-
morpholino]- ethanesulfonic acid, (MES), 0.9 M NaCl, 0.02% NaN3, pH 4.7 with 
500 µg of [1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride], 
(EDC), in an overnight reaction.  The KLH-Gal conjugate was purified from 
unreacted materials using a size exclusion spin column and recovered in 0.5 ml 
of elution buffer (8 mg/ml).  Sterile water for injection was used to produce the 
conjugation and column elution buffers for the conjugation reaction.  This 
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material was stored at – 20 oC until used.  Prior to immunization the KLH-Gal 
was diluted to 2 mg/ml in sterile saline and mixed with vigorous vortexing with 
an equal volume of Freund’s incomplete adjuvant.  Animals were immunized 
with 0.1 ml (100 µg KLH-Gal) by intraperitoneal injection at 30 days of age.   
To test the efficiency of conjugation, KLH-Gal was diluted to 10 µg/ml in 
carbonate buffer and coated on an ELISA plate.  Lectin binding to the KLH-Gal 
conjugate was compared to KLH, BSA and BSA-Gal. 
2.13 Calcium measurement 
Calcium analysis on explanted porcine pericardium disks was done in 
collaboration with Professor John McArthur, Professor of Geology, UCL Earth 
Sciences, using inductively coupled plasma spectroscopy.  Preparation of the 
samples for analysis was done by Dr Heide Kogelberg (UCL Institute of 
Cardiovascular Science, Cardiothoracic Surgery and Interventional Medicine 
Group). 
Fixed but not implanted WT and GTKO porcine pericardium disks served as 
negative controls for calcium content prior to implantation.  Explanted 
pericardial samples were cleared of any encapsulating materials and rinsed in 
sterile saline.  The tissues were placed in weighed microcentrifuge tubes and 
dried at 65 oC for 20 hours.  Then the microcentrifuge tube with the pericardium 
was weighed and the tissue dry weight was recorded.  Dried pericardium was 
transferred to 8 ml glass vial and hydrolysed with 0.5 ml of concentrated nitric 
acid at 65 oC for 15 min with periodic vortexing after which 0.5 ml hydrogen 
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peroxide was added, mixed well and incubated at 65 oC for an additional 15 
minutes.  The sample was vortexed until tissue was completely dissolved.  The 
dissolved materials were diluted with 3 ml of nanopure water, mixed well and 
0.2 ml was transferred to a Sarstedt tube with 4.9 ml 1% nitric acid.  Samples 
were then analysed in a 720 ICP-AES, axial configuration Inductively Coupled 
Plasma-Optical Emission spectrometer (Varian, USA). 
Internal calcium standards were analysed as controls during each analysis.  
Calcium chloride dihydrate was dissolved in ultrapure water, hydrolysed as 
indicated above and diluted to produce calcium standards ranging from 0 to 5 
μg/ml.  These standards were run with each analysis and a blank and mid-
range standard were repeated at regular intervals in each analysis to monitor 
and adjust for instrument drift. 
2.14 Histology 
Immunohistochemistry 
Glutaraldehyde fixed pericardium or valve leaflets were embedded in optimal 
cutting temperature control compound (OCT), frozen and 8 micron sections cut 
with a Leica CM3050 cryostat.  Sections were air dried and fixed in acetone for 
10 minutes and frozen at – 80 oC until used.  Tissue sections were thawed, air 
dried and circled with Pap Pen.  The hydrophobic Pap Pen perimeter was left to 
air dry for 2 hours prior to staining.  Slides were washed with water for 5 min in 
two changes to remove OCT, incubated in PBS for 10 minutes and blocked with 
1% BSA in DPBS for 60 min, room temperature.  Sections were incubated with 
GSIB4 (2 µg/ml diluted in DPBS with 1% BSA) overnight, at 4 C, washed 3 
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times with PBS, 3 min each, blocked with 1% BSA in DPBS for 30 min, room 
temperature and incubated with streptavidin HRP (1:500) for 60 min, room 
temperature.  The sections were washed 3 times with PBS 3 min each and 
stained with 3,3'- diaminobenzidine (DAB) for 5-15 min, room temperature.  
After staining the sections were washed extensively with water and counter 
stained with acid-Haematoxylin using standard techniques.  Slides were 
subsequently dehydrated through an ethanol series (70% – 100% ethanol) and 
HistoClear prior to making a permanent mount in Perimount. 
Immunohistochemistry staining for α-Gal with haematoxylin and eosin (H & 
E) counter stain was performed by our lab technician Miss Elisa Chisari. 
Von Kossa and H&E staining of explanted pericardium were done by the 
UCL IQ Path facility, UCL Institute of Neurology. 
2.15 Statistical analysis 
GIE results are represented as mean values ± standard error of the mean 
(SEM).  Comparisons of effective inhibition between different genotypes and 
different incubation conditions or different anticalcification treatments were 
analysed using student’s t-test (two-tailed distribution, two-sample equal 
variance).  P-values less than 0.05 were considered significant.   
Sigmaplot software was used for curve fitting and to calculate IC50 values 
based on a four parameter logistic curve for the inhibition profiles of anti-Gal 
reagents with monomeric α-Gal trisaccharide.  Excel was used for semi-log 
curve fitting to calculate mouse anti-Gal IgM and IgG titres. 
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Calcium content values and antibody titres are presented as mean values ± 
SEM.  Comparisons between different implantation groups were analysed using 
t-test as described above.  Linear regression and correlation analysis between 
calcification levels of WT implanted pericardium and anti-Gal IgM and IgG titres 
were performed using the corresponding Data Analysis tools in Excel.  As some 
of the data was not normally distributed, the Spearman’s rank correlation was 
calculated (rs) in addition to Pearson correlation coefficient (r). 
2.16   Laboratory work and summary of collaborative contributions 
I performed all aspects of the laboratory work involving the enzymatic cycling 
reaction, hybridoma and endothelial cell culture, anti-Gal hybridoma purification, 
flow cytometry staining and analysis, Gal inhibition ELISAs, pig pericardium 
fixation and anticalcification processing, mouse serum anti-Gal antibody titration 
ELISAs, α-galactosidase digestion of cells or pericardium, as well as mice 
genotyping.  Some of the mouse anti-Gal antibody ELISAs to determine the IgG 
titres were performed under my direction and training by Elisa Chisari.   
Immunohistochemical staining for α-Gal with H&E counter stain was 
performed by technician Elisa Chisari.  Von Kossa staining for calcium and H&E 
of explanted pericardium was done by the UCL IQ Path facility, UCL Institute of 
Neurology. 
Calcium measurement on explanted pericardium was done in collaboration 
with Prof John McArthur, Professor of Geology, UCL Earth Sciences.  Samples 
were prepared for calcium analysis by Dr Heide Kogelberg. 
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I was trained in general animal procedures, as part of getting my personal 
licence, by taking part in a series of required training courses (modules 1,2, 3,4) 
at the Royal Veterinary College.  Specific training for the subcutaneous implant 
surgeries was from Dr Guerard Byrne.  I performed all of the surgeries and Dr 
Byrne assisted with induction and maintaining anaesthesia during surgery.  
Retrieval of explants and terminal blood collection via cardiac puncture was 
performed by me.  Due to its highly technical nature blood collection via cardiac 
puncture was supervised and assisted by the unit’s technologists. 
77 
 
 
 
 
RESULTS 
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3 Enzymatic detection of galactose 
We initially tried to adapt an enzymatic method used to measure lactose to 
detect α-linked galactose.  In this approach galactose was released by digestion 
with α-galactosidase and the amount of galactose was measured by reacting 
with GH.  GH in the presence of NAD produces NADH in stoichiometric 
amounts from galactose.  NADH can be directly measured by measuring its 
absorbance at 340 nm.  Initial tests of this reaction using galactose 
concentrations ranging from 39 µM to 10,000 µM showed that NADH could be 
detected, but the sensitivity of the method was low.  Galactose concentrations 
of 312.5 µM or higher were required for reliable detection (Figure 3.1A).  This 
was equivalent to approximately 1.8 x 1020 molecules of galactose. 
 
 
 
 
 
Figure 3.1  NADH production from galactose by galactose dehydrogenase.  Different 
concentrations of galactose were incubated with galactose dehydrogenase (GH) and 
stoichiometric amount of NADH was produced.  A: The NADH produced by GH was measured by 
spectrophotometry at 340 nm.  B: Formazan was produced using enzymatic cycling to amplify the 
signal of the NADH produced by GH from galactose (blue line), or by testing NADH standard 
concentrations (red line). 
79 
 
Using conservative estimates, the amount of α-Gal derived from small samples 
of BHVs or pig tissue was expected to be much lower, in the order of 1011 α-Gal 
epitopes/mg porcine tissue (Stone et al. 2007).  To improve the sensitivity for 
detecting NADH an enzymatic cycling system (CycLex, MBL) was used.  This 
enzymatic cycling system has the potential to detect 0.0156 µM NADH, which is 
equal to 9.4x1015 molecules.  When the cycling system was coupled with the 
GH reaction, the lower limit of detection was approximately 1 µM galactose 
(6.022x1017 molecules) (Figure 3.1B). 
Although the GH reaction and the enzymatic cycling system reactions were 
coupled successfully, they did not provide a satisfactory level of sensitivity.  A 
very large amount of tissue or cells would still be required to detect galactose 
within that range of sensitivity, as 6.022x1017 molecules galactose 
corresponded to 6 kgrams of pig tissue.  This sensitivity would probably be 
further decreased by addition of another enzymatic step, that of α-galactosidase 
reaction, so the method was not further pursued. 
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4 Inhibition ELISA with different anti-Gal reagents 
4.1 Development of the assay 
4.1.1 Anti-Gal reagents inhibition with α-Gal 
A Gal inhibition ELISA was developed to measure α-Gal on solid substrates 
(Figure 2.3).  In this assay the amount of α-Gal on tissue or cells was estimated 
by the reduced amount of free anti-Gal reagent available to bind in a Gal ELISA.  
Three different anti-Gal reagents were tested - GSIB-4, which is a lectin widely 
used to detect α-linked galactose and mouse anti-Gal monoclonal antibodies 
M86 (IgM) and GT5 (IgG).  Prior to the inhibition ELISA the concentration of 
each anti-Gal reagent which yielded approximately 70% of their maximal 
binding in the BSA-Gal ELISA was determined (0.125 µg/ml GSIB-4 lectin, 1:10 
M86 IgM supernatant and 1µg/ml GT5 IgG) (Figure 4.1).  These concentrations 
were selected for the inhibition studies, as they provide a sufficient dynamic 
range in which to measure depletion of free anti-Gal reagent by the test 
material. 
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To further characterize these reagents each was mixed at a set 
concentration with serial dilutions of free α-Gal trisaccharide (tri-α-Gal) at 4 oC 
overnight to produce an inhibition profile (Figure 4.2). 
 
Figure 4.1  Anti-Gal reagents’ binding to BSA-Gal.  Serial dilutions of biotinylated GSIB-4 
and anti-Gal monoclonal antibodies M86 and GT5 were tested in duplicate (50 µl/ well) in a 
microtiter plate coated with 10 µg/ml BSA-Gal, for 90min, at 4
o
C.  GSIB-4 (0.0039 - 1 µg/ml) 
binding was detected with extravidin-peroxidase (1:1000) incubated at RT for 1 hour.  
Detection of M86 (serial dilutions from 1:1 to 1:1280) and GT5 (0.001 – 1 µg/ml) was done 
using a biotin-conjugated anti-mouse IgM or IgG, respectively and then detected with 
extravidin-peroxidase.  A: GSIB-4, B: M86 IgM, C: GT5 IgG. 
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For each reagent a sigmoid binding curve to BSA-Gal was observed.  The 
position of this curve on the x axis is a measure of the relative avidity of each 
reagent to BSA-Gal.  At half maximal inhibition by free tri-α-Gal monomer an 
IC50 (half maximal inhibitory concentration) could be defined.  The pentameric 
anti-Gal IgM M86 with 10 α-Gal binding sites had the highest IC50 (2089 µM).  
The lectin GSIB-4 with 4 α-Gal binding sites had an IC50 of 323 µM.  The 
lowest apparent avidity was seen with anti-Gal IgG GT5 (285 µM).  This 
indicates that nearly 6.5 times more tri-α-Gal monomer is required to inhibit M86 
binding to BSA-Gal by 50% compared to GT5 or GSIB-4.  The apparent avidity 
Figure 4.2  The inhibition of anti-Gal reagents by free α-Gal trisaccharide 
(tri-α-Gal).  The graph shows the inhibition profiles of anti-Gal reagents [GSIB-4 
lectin (blue), GT5 IgG (red) and M86 IgM (green)].  A constant concentration of 
each reagent was incubated with serial dilutions of tri-α-Gal and then tested for 
residual binding by ELISA using BSA-Gal as a solid phase antigen.  Curves 
were fitted as four parameter logistic curves using the SigmaPlot 10.0 software.  
The points at which the dotted lines meet the x axis represent the IC50 values 
for each reagent which produced 50% inhibition in the Gal ELISA.  Each curve is 
an aggregate inhibition profile derived from several independent studies.  
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for each reagent is strongly dependent on the number of binding sites, but it is 
also expected to be affected by the affinity of each binding site.  
To confirm specific binding to α-Gal each reagent was tested for binding to 
Gal-positive or GTKO PAECs by flow cytometry.  Binding to GTKO PAECs was 
used as a negative control.  GSIB-4 lectin and M86 IgM bound to Gal-positive 
PAECs but not to GTKO cells (Figure 4.3 A and B).  The anti-Gal GT5 IgG 
bound strongly to Gal-positive PAEC, but also surprisingly showed residual 
binding to GTKO cells (Figure 4.3C).  Because of this background binding to 
GTKO PAEC GT5 was not used in additional experiments. 
 
 
 
 
 
4.1.2 M86 IgM binding on PAEC 
M86 was incubated at 4oC overnight with different numbers of Gal-positive 
PAECs, (0.5 – 7.5) x106 cells.  Under these conditions increasing numbers of 
Figure 4.3  Binding of anti-Gal reagents on Gal positive and GTKO PAECs tested by flow 
cytometry.  Cells were incubated with:  A: GSIB-4, B: M86 or C: GT5.  Binding of the anti-Gal 
reagents was detected with PE-conjugated streptavidin (GSIB-4), FITC-conjugated rat anti-
mouse IgM (M86), or PE-conjugated goat anti-mouse IgG (GT5).  In each histogram, the green 
line represents binding to Gal-positive cells and the blue line binding to GTKO cells.  The grey 
filled line represents a negative control where cells were stained with only the respective 
secondary reagent.  Y axis represents counts. 
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PAECs bound to proportionally higher amounts of M86, as judged by the 
apparent depletion of free M86 available for binding in the Gal ELISA (Figure 
4.4A).  In parallel to this cellular inhibition M86 was incubated with free tri-α-Gal 
under the same conditions.  This resulted in an inhibition curve (Figure 4.4B).  
The inhibitory effect of tri-α-Gal against M86 binding was evident at 
concentrations higher than 1200 µM (log3.08) and reached approximately 100% 
at concentrations of approximately 3100 µM (log3.49) or higher. 
 
 
By comparing these curves an equivalent amount of free monomeric α-Gal 
which produced a specific degree of inhibition could be related to the number of 
cells which produced the same degree of inhibition.  For cell numbers within the 
range of 0.5x106 up to 7.5x106 the equivalent amounts of α-Gal were in the 
Figure 4.4  M86 IgM antibody inhibition by α-Gal.  A: Graph shows inhibition of M86 binding 
to BSA-Gal ELISA by Gal-positive [Gal(+)] PAECs (blue line) or GTKO EC cell line (red).  Each 
point for the Gal(+) PAECs shows the mean ± SEM of three independent experiments.  Each 
sample was measured in duplicate.  The GTKO cell line results are from a single experiment.  
B: Inhibition of a constant concentration of M86 by serial dilutions of free α-Gal trisaccharide (tri-
α-Gal).  The graph depicts the inhibition profiles for M86 from two independent experiments, 
each indicated by a different symbol.  The point at which the dotted line meets the x axis 
represents the tri-α-Gal concentration which produces 50% inhibition (IC50) of M86 binding in 
the Gal ELISA.  The curve was fitted as a four parameter logistic curve using the SigmaPlot 
10.0 software. 
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range of 1800 µM – 2600 µM (Table 1).  For 50% inhibition of M86 by α-Gal-
positive PAECs we calculated that 1.6x106 PAECs are required. 
 
Table 1  Gal(+) PAECs and equivalent concentrations of α-Gal monomer that produce the same 
degree of M86 inhibition in the Gal ELISA. 
Gal(+) PAECs (*10
6
) % Inhibition Equivalent α-Gal (µM) 
0.5 31.8 1805.2 
1.6 50.0 2089.0 
4.0 62.7 2302.5 
7.5 74.9 2568.7 
 
The specificity of M86 binding was further tested in the inhibition assay by 
binding to GTKO PAECs under the same conditions (Figure 4.4A, red line).  
Incubation with GTKO cells did not produce appreciable inhibition of M86 
binding in the Gal-ELISA.  Even at high concentrations of up to 7.5x106 GTKO 
cells M86 inhibition was only 10%, consistent with non-specific background 
binding to cells. 
4.1.3 GSIB-4 binding on PAEC 
Similar to the analysis of M86, an inhibition profile for GSIB-4 was produced.  
GSIB-4 bound on α-Gal-positive PAECs as determined by the increasing 
percentage of inhibition in the Gal ELISA (Figure 4.5A).  A monomeric α-Gal 
inhibition curve for GSIB-4 lectin was done in parallel (Figure 4.5B) and was 
used to compute the equivalent amount of α-Gal monomer required to match 
inhibition by α-Gal-positive PAECs (Table 2). 
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Inhibition of GSIB-4 by Gal-positive PAECs (0.5 – 8 *106) was equal to 
inhibition by 245 µM – 569 µM α-Gal monomer.  We calculated an IC50 for 
GSIB-4 inhibition of 1.3x106 cells. 
Table 2  Gal(+) PAECs and equivalent concentrations of α-Gal monomer that produce 
the same degree of GSIB-4 inhibition in the Gal ELISA. 
Gal(+) PAECs (*106) % Inhibition Equivalent α-Gal (µM) 
0.5 31.5 245.6 
1.0 45.6 302.9 
1.3 50.0 322.9 
2.0 58.5 367.5 
4.0 71.4 465.0 
8.0 79.1 569.5 
 
Figure 4.5  GSIB-4 lectin inhibition by α-Gal.  A: Graph shows inhibition of GSIB-4 binding to 
BSA-Gal ELISA by Gal-positive PAECs.  Each point shows the mean ± SEM of three independent 
experiments.  Each sample was measured in duplicate.  B: Inhibition of a constant concentration 
of GSIB-4 by serial dilutions of free α-Gal trisaccharide (tri-α-Gal).  The graph depicts the 
inhibition profiles for GSIB-4 from two independent experiments.  The point at which the dotted 
line meets the x axis represents the tri-α-Gal concentration which produces 50% inhibition (IC50) 
of GSIB-4 binding in the Gal ELISA.  The curve was fitted as a four parameter logistic curve using 
the SigmaPlot 10.0 software. 
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Despite the 6-fold difference in apparent avidity between M86 and GSIB-4 
(Figure 4.2) both reagents bound to Gal-positive PAEC with nearly identical 
IC50s and producing similar inhibition profiles (Figure 4.6).  
 
 
 
 
 
4.1.4 GSIB-4 and fixed pig pericardium 
We used glutaraldehyde (0.6%) fixed pig pericardium as a model 
bioprosthetic tissue.  To use the inhibition assay for measuring α-Gal content of 
this tissue we first tested the duration of incubation.  Fixed, 3mm diameter, 
pericardium disks (n=4) were incubated with GSIB-4 at 4oC, overnight and up to 
3 days (Figure 4.7). 
 
Figure 4.6  Comparison of the inhibition profiles of GSIB-4 lectin and IgM 
antibody M86 with Gal-positive PAECs.  GSIB-4 (blue line), M86 (red line).  
Graph shows the mean values ± SEM of three independent experiments for each 
reagent.   
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Overnight (ON) incubation resulted in approximately 14% inhibition which 
increased significantly to 36% in 2-day incubation.  No further increase in GSIB-
4 binding occurred with longer incubation times.  For ON and 2-day incubations 
there was little binding to GTKO pericardium.  In contrast at 3-day incubation 
with GTKO pericardium there was an apparent increase in GSIB-4 binding in 
the Gal ELISA (negative inhibition) (Figure 4.7).  This suggested that prolonged 
incubation does not improve lectin binding to Gal-positive tissue and may create 
an artefact in the Gal ELISA.  When fixed heterozygous, GT(+/-), pericardium 
was tested in comparison to GT(+/+) and GTKO, in ON (Figure 4.8A) and 2-day 
(Figure 4.8B) incubations, the differences in inhibition levels produced by α-Gal-
Figure 4.7  Testing the duration of incubation for GSIB-4 binding to fixed 
pig pericardium.  The graph shows GSIB-4 inhibition by wild type (+/+) and 
GTKO (KO) fixed pig pericardium after overnight (ON), 2 days and 3 days 
incubation.  All experiments were performed using four (3mm diameter) disks 
incubated with GSIB-4 for the indicated times.  Each bar represents the mean ± 
SEM of a minimum of 8 independent samples.  Results of student’s t-test are 
indicated by p-values.  NS: not significant. 
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positive and GTKO tissue were more significant after 2-day incubation (Figure 
4.8B).  We selected 2 days as the standard duration for incubation.  
 
 
 
 
 
Increasing the number of disks was expected to increase the level of 
inhibition.  We tested whether the increase of antigen would improve the 
sensitivity of the assay by comparing lectin binding to Gal-positive homozygous 
(GT+/+), heterozygous (GT+/-) and GTKO pericardium.  The number of 
pericardium disks used per sample was increased from 4 to 8.  Increasing the 
amount of antigen resulted in increased GSIB-4 binding and increased inhibition 
in the Gal ELISA (Figure 4.9B).  Maximal inhibition for GT(+/+) increased from 
36.1 ± 8.9 % (using 4 disks) to 50.2 ± 7.2 % (using 8 disks).  Background 
binding to GTKO tissue remained low.  Under these conditions GSIB-4 binding 
to GT(+/-) tissue resulted in 38 ± 6.4 % inhibition.  This was significantly less 
than GSIB-4 binding to GT(+/+) tissue.  A significant difference in GSIB-4 
binding between GT(+/+) and GT(+/-) tissue was not detected when 4 disks of 
pericardium were used (Figure 4.9A). 
Figure 4.8  Comparing overnight (ON) and 2-day incubation for GSIB-4 lectin binding to 
fixed pig pericardium.  Graphs depict the apparent inhibition of GSIB-4 binding in the Gal 
ELISA by fixed pig pericardium.  Three different genotypes of pericardium were tested- Gal-
positive homozygous (+/+), heterozygous (+/-) and Gal knock-out (KO).  A: Overnight 
incubation.  B: 2-day incubation.  Data are expressed as mean ± SEM.  A minimum of four 
samples (each with four, 3mm diameter, disks incubated with GSIB-4) of each genotype were 
used and three independent experiments were performed.  Results of student’s t-test are 
indicated by p-values. 
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This suggests that 8 glutaraldehyde fixed, 3mm diameter, pericardium disks 
with 2 days incubation at 4oC represent optimal conditions for the inhibition 
assay.  These conditions were thus used to examine M86 binding on fixed pig 
pericardium. 
4.1.5  M86 binding on fixed pig pericardium 
M86 antibody (1:10 dilution) was incubated with 8 pericardium disks at 4oC 
for 2 days.  Under these conditions both GT(+/+) and GT(+/-) pericardium 
bound significantly more M86 than GTKO pericardium causing a higher 
apparent inhibition in the Gal-ELISA.  M86 binding to GT(+/+) (25.6 ± 6.47 %) 
was higher than binding to GT(+/-) pericardium (18.4 ± 2.13 % ).  However, this 
did not reach significance (Figure 4.10). 
Figure 4.9  Comparing the effects of 4 versus 8 disks on GSIB-4 binding to fixed pig 
pericardium.  Graphs depict the apparent inhibition of GSIB-4 binding in the Gal ELISA.  Three 
different genotypes of pericardium were tested- Gal-positive homozygous (+/+), heterozygous 
(+/-) and Gal knock-out (KO).  A: Four or B: eight disks (3mm diameter) of fixed pig 
pericardium per sample were incubated with GSIB-4 for 2 days.  Data are presented as mean ± 
SEM.  Minimum four samples of each genotype were used and three independent experiments 
were performed.  Results of student’s t-test are indicated by p-values.  The asterisk indicates 
that the increase in inhibition produced by 8 (+/+) disks compared to 4 (+/+) disks was highly 
significant. 
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GSIB-4 and M86 showed similar binding to α-Gal-positive PAECs, but 
showed different levels of apparent inhibition when incubated with fixed 
pericardium.  Binding of GSIB-4 to fixed pig pericardium appeared to be more 
effective, as higher inhibition was produced by α-Gal-positive pericardium 
compared to M86 (Figure 4.11). 
 
Figure 4.10  M86 inhibition by fixed pig pericardium.  Graphs 
depict the apparent inhibition of M86 binding in the Gal ELISA by 
fixed pig pericardium.  Three different genotypes of pericardium were 
tested- Gal-positive homozygous (+/+), heterozygous (+/-) and Gal 
knock-out (KO).  Four independent samples of each genotype (each 
sample with eight, 3mm diameter, disks incubated with M86) were 
tested.  Data are presented as mean ± SEM.  Results of student’s t-
test are indicated by p-values. 
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Furthermore, GSIB-4 detected a significant difference in α-Gal levels between 
homozygous and heterozygous α-Gal-positive pericardium (Figure 4.11).  This 
suggests that despite the higher apparent avidity of M86 for BSA-Gal, GSIB-4 is 
more effective for measuring α-Gal in fixed pig pericardium under these 
conditions.  
4.2 Determining inhibition ELISA’s sensitivity 
The aim of the following experiments was to estimate the sensitivity of the α-
Gal inhibition ELISA (GIE), by measuring the smallest reduction in α-Gal 
content that can be reliably detected by this assay.  To accomplish this I used α-
galactosidase digestion to partially remove α-Gal epitopes from WT PAECs.  I 
then used both GIE and quantitative flow cytometry to measure the changes in 
α-Gal expression on PAECs.  By comparing these two methods I defined the 
Figure 4.11  Comparison of GSIB-4 and M86 binding to fixed 
pig pericardium.  Graphs depict the apparent inhibition of GSIB-
4 and M86 binding in the Gal ELISA by fixed pig pericardium.  
Three different genotypes of pericardium were tested - Gal-
positive homozygous (+/+), heterozygous (+/-) and Gal knock-out 
(KO).  Bars represent averaged results of 3 independent 
experiments.  Data are presented as mean ± SEM. 
93 
 
minimal reduction in α-Gal levels, as measured by flow cytometry, to identify the 
minimal change in α-Gal required to get reliable detection by the GIE.  
WT PAECs were treated with α-galactosidase to cleave terminal α-Gal 
epitopes.  Subsequently the cells were stained with biotin-conjugated lectin 
GSIB-4.  Binding of GSIB-4 to PAECs was detected by streptavidin-PE or 
streptavidin-AlexaFluor 488.  GTKO PAECs that do not express α-Gal were 
used as a negative control. 
Digestion of PAECs with increasing concentrations of α-galactosidase 
resulted in progressive removal of increasing amounts of α-Gal epitopes from 
the cell surface.  This resulted in correspondingly reduced binding of GSIB-4 
(Figure 4.12). 
 
Figure 4.12  FACS histograms of WT PAECs digested with increasing 
concentrations of α-galactosidase.  WT PAECs were treated with a range 
of α-galactosidse concentrations (1 – 10 units/ml).  Subsequently cells were 
stained with GSIB-4 and streptavidin-PE.  The above histogram depicts 
GSIB-4 binding to non-digested WT PAECs (filled green histogram), to 
PAECs after digestion with 1 (brown line), 2.5 (purple line), 5 (blue line), 7.5 
(orange line) and with 10 units/ml (red line) α-galactosidase.  The grey filled 
histogram represents GSIB-4 binding to GTKO PAECs.  Y axis represents 
counts. 
94 
 
The results in Figure 4.12 can be presented as a graph depicting mean 
fluorescence intensity (MFI) of GSIB-4 binding in relation to the α-galactosidase 
concentrations.  This representation clearly shows that increasing levels of α-
galactosidase progressively reduced the expression of α-Gal epitopes and 
proportionately reduced the level of GSIB-4 binding to cells (Figure 4.13). 
Flow cytometry is an accepted standard quantitation method for determining 
the level of antigen expression on cells.  This FACS data can be used to 
calculate the percentage of reduction of GSIB-4 binding compared to the MFI of 
non-digested PAECs using the following equation: 
Equation D: 
 
 
In this individual experiment there was a reduction of MFI from 11,626 to 
2262 at 10 units/ml of α-galactosidase representing a 80.55 % reduction of 
lectin binding (Figure 4.13). 
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Figure 4.13 Mean fluorescence intensity (MFI) of PAECs stained with GSIB-4 after α-
galactosidase treatment.  The graph depicts the progressive reduction in GSIB-4 binding to 
WT PAECs after treatment with rising concentrations of α-galactosidase.  This is a 
representative FACS analysis of a single digestion experiment. 
 
 
A-galactosidase digestion within a range of (2-8) units/ml was used to 
consistently achieve moderate reduction in α-Gal epitopes.  These experiments 
showed a consistent reduction in α-Gal level producing PAECs with reliably 
intermediate levels of α-Gal.  A reduction of 12% to 40% of α-Gal antigen was 
demonstrated after digestion with a range of 2 to 8 units/ml of α-galactosidase 
(Figure 4.14). 
By calculating the percentage of reduction in MFI we could monitor the loss 
of α-Gal antigen due to α-galactosidase digestion. 
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Figure 4.14  Average reduction in GSIB-4 binding to WT PAECs after α-galactosidase 
digestion measured by FACS. The graph shows the percentage of MFI reduction after 
digestion of WT PAECs with α-galactosidase.  This reduction corresponds to reduction in α-Gal 
epitopes.  Each point represents mean value from a minimum of 6 samples at each enzyme 
concentration.  Error bars represent SEM. 
 
To gauge the sensitivity of the GIE, WT PAECs were treated with α-
galactosidase and the reduction in α-Gal antigen was measured by GIE and 
flow cytometry in parallel.  After digestion PAECs (250,000) were stained with 
GSIB-4 for FACS analysis and the remaining cells (1.25x106) were used in the 
GIE assay.  For the GIE inhibition was expressed as a percentage in 
comparison to the background binding of GSIB-4 to fixed GTKO PAECs as 
calculated by the following equation: 
Equation E 
% Inhibition =  (OD GTKO- OD sample)*100 / OD GTKO 
OD GTKO: the GIE optical density measured in the presence of GTKO PAECs. 
OD sample: the GIE optical density measured in the presence of WT PAECs 
either treated or not treated with α-galactosidase. 
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With progressive α-galactosidase digestion the level of α-Gal antigen on 
PAECs was proportionately reduced.  This led to a reduction of GSIB4 binding 
to the cells with a corresponding increase in free GSIB-4 available to bind in the 
α-Gal ELISA.  The result was an apparent reduction in inhibition with increasing 
enzyme levels (Figure 4.15). 
To compare the GIE and flow cytometry results we calculated the reduction 
in inhibition levels for the GIE (Figure 4.15 B) and compared that to the reduction 
in MFI for flow cytometry (Figure 4.16).  This was expressed as a percentage of 
the inhibition produced by α-galactosidase digested PAECs compared to the 
inhibition produced by non-digested PAECs and was calculated from the 
following equation: 
Equation F 
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Figure 4.15  Effects of α-galactosidase digestion on the α-Gal inhibition ELISA (GIE) 
assay.  A) The graph depicts the per cent inhibition observed in the GIE assay after α-
galactosidase digestion of PAECS from a single representative experiment.  Removal of α-Gal 
epitopes on PAECs with α-galactosidase reduced GSIB-4 binding and increased the level of 
free GSIB-4 available for the α-Gal ELISA.  This leads to reduced inhibition in the α-Gal ELISA 
with increasing levels of α-galactosidase.  B) Reduction in inhibition after α-galactosidase 
digestion.  Transformation of the data in Figure 4.15A shows the apparent reduction in GIE 
with increasing α-galactosidase. The graph depicts the same data as presented in figure 4.15A. 
 
 
By this comparison we could estimate the relative sensitivity of the GIE.  The 
flow cytometry results showed a consistent reduction in α-Gal antigen (Figure 
4.16) progressing from 15% to 40% reduction in GSIB-4 binding when using (2-
8) units/ml α-galactosidase.  In comparison the GIE appeared to be somewhat 
less sensitive showing only a 12% to 28% reduction across the same range of 
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α-galactosidase treatment.  Moreover, at low α-galactosidase levels (2 – 4 
units/ml) the GIE could not reliably distinguish the change in α-Gal expression. 
 
 
Figure 4.16 Reduction of α-Gal on PAECs after α-galactosidase digestion estimated by 
FACS or α-Gal inhibition ELISA.  Both FACS and α-Gal inhibition ELISA showed that 
increasing concentrations of α-galactosidase resulted in progressive reduction in α-Gal levels 
from the cells surface.  Each point shows the mean ± SEM from a minimum of four experiments.  
The differences in reduction of α-Gal levels between 8 units/ml of enzyme and 4 units/ml or 8 
and 2 units/ml were significant for both methods.  However none of the methods detected a 
significant difference in α-Gal levels between digestion with 4 and 2 units/ml.  Significant 
differences are indicated by asterisks (p<0.05). 
 
 
This suggests that the smallest reduction in α-Gal levels that can be 
detected by GIE is approximately a 20% decrease.  We expect that this level of 
sensitivity is sufficient for the GIE to detect biologically meaningful decreases in 
α-Gal levels which may occur on fixed tissues after anticalcification treatments. 
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4.3 Summary and discussion of results 
I managed to develop a robust Gal inhibition ELISA (GIE) assay for 
measuring α-Gal on cells and fixed tissue using two different anti-Gal reagents, 
lectin GSIB-4 and IgM M86.  Both reagents bound to PAECs in a similar way, 
but GSIB-4 was more sensitive for binding to fixed pig pericardium.  It detected 
significant differences between homozygous and heterozygous α-Gal positive 
tissue, while M86 could not distinguish between them.  To determine the 
sensitivity of the GIE I used α-galactosidase digestion of PAECs to partially 
remove α-Gal and estimated the reduction in α-Gal levels using flow cytometry 
and GIE.  These changes in α-Gal levels were expressed as percentage of 
reduction in MFI and percentage of reduction in inhibition ELISA, so that the 
sensitivity of the two methods could be compared.  The sensitivity for the GIE 
assay was estimated at approximately 20% reduction in α-Gal levels, 
suggesting that GIE assay can be used to study the effect of anticalcification 
treatments to fixed tissue. 
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5 Effects of anticalcification processing on α-Gal levels in 
fixed animal tissue 
Anticalcification treatments are used in industry to reduce the level of 
phospholipids which are thought to be sites for calcium deposition.  These 
anticalcification processes are highly effective in the subcutaneous implant (rat 
and rabbit) and juvenile sheep valve implant models.  While these animal 
models do not produce anti-Gal antibody and thus calcification is likely due to 
passive plasma calcium binding and crystal growth, none-the-less phospholipid 
extraction may also reduce the level of α-Gal antigen by removing glycolipids 
and this might help to reduce antibody mediated injury of BHVs.  We used the 
GIE with GSIB-4 (GIE GSIB-4) and M86 (GIE M86) to assess the level of α-Gal 
reduction caused by various anticalcification processing methods. 
Porcine pericardium or heart valve leaflets were fixed in 0.6% glutaraldehyde 
and then treated with glutaraldehyde capping (glycine), phospholipids extraction 
using either ethanol, SDS or a combination of formalin, ethanol and Tween 
(FET).  Controls included fixed tissue treated with α-galactosidase and GTKO 
tissue subjected to the same capping, enzymatic or lipid extraction procedures 
to control for potential effects on non-specific GSIB-4 or M86 binding.   
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5.1 GIE GSIB-4 assessment of α-Gal levels after anticalcification of 
porcine pericardium 
WT porcine pericardium causes an apparent GIEGSIB-4 inhibition (50.27 ± 
2.00 %) which was significantly higher than the non-specific inhibition by GTKO 
pericardium (20.5 ± 0.87 %).  Overall, the anticalcification treatments had little 
effect on α-Gal levels in WT pericardium.  GIEGSIB-4 inhibition for anticalcification 
treatments ranged from 36% to 57%, comparable to those of untreated WT 
tissue (Figure 5.1A).  Extraction with SDS was the only treatment to significantly 
reduce α-Gal levels, lowering GIEGSIB-4 inhibition to 36.67 ± 3.37 %.  This 
represents a moderate (27.05%) reduction of α-Gal antigen by SDS extraction.  
In contrast, α-galactosidase treatment effectively stripped α-Gal antigen from 
the pericardium with GIEGSIB-4 inhibition levels of 17.33 ± 2.20 %, similar to non-
specific GTKO inhibition (Figure 5.1A). 
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Figure 5.1 GIE GSIB-4 estimates of α-Gal antigen on fixed porcine pericardium after 
processing with anticalcification treatments.  A) WT pericardium (blue) was fixed with 
glutaraldehyde (GLUT) and subsequently processed with glycine for glutaraldehyde quenching, 
with formaldehyde–ethanol–Tween 80 (FET), sodium dodecyl sulfate (SDS) or ethanol (EtOH) 
to extract phospholipids.  GLUT fixed pericardium was also treated with α-galactosidase to 
remove α-Gal epitopes.  GTKO pericardium (light blue) was similarly treated to account for non-
specific lectin absorption.  Each bar represents the mean of a minimum of six test samples for 
WT pericardium and 2 samples for GTKO pericardium.  The asterisk indicates the significantly 
(p<0.05) lower α-Gal levels in SDS treated tissue compared to the GLUT fixed tissue (control 
tissue).  B) α-Gal antigen levels in a commercial pericardial valve, Carpentier-Edwards 
PERIMOUNT Plus 6900P (purple).  Error bars represent standard error of the mean (SEM). 
 
We also examined the level of α-Gal antigen present on a commercial 
Carpentier-Edwards PERIMOUNT Plus 6900P bovine pericardial mitral valve 
(Edwards Lifesciences, CA, USA).  This valve was treated with the company’s 
XenoLogiXTM tissue processing which is reported to eliminate up to 90% of 
phospholipids and is similar to the FET treatment we have used.  The 
PERIMOUNT Plus 6900P valve retains a high level of α-Gal antigen as evident 
by the high GIEGSIB-4 inhibition (66.27 ± 7.90 %) (Figure 5.1B). 
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5.2 GIE M86 assessment of α-Gal levels after anticalcification of 
porcine pericardium 
Anticalcification treatments may alter the surface of the tissue and affect 
presentation and accessibility of various antigens.  The α-Gal-specific reagents 
GSIB-4 and anti-Gal IgM M86 are very different molecules with different sizes 
that have been widely used to detect α-Gal antigen.  Due to their different 
structure and size they may have differential access to α-Gal epitopes.  
Therefore we also used a GIEM86 assay to estimate any changes in α-Gal levels 
on anticalcification processed tissue.  Using both reagents helped to provide a 
more complete evaluation of anticalcification treatments. 
A-Gal antigen levels after anticalcification processing were also measured 
using the GIEM86 inhibition ELISA.  Consistent with previous results, glycine 
capping and the anticalcification treatments (FET, SDS, EtOH) alone or in 
combination had little effect on α-Gal levels as measured by the GIEM86 (Figure 
5.2).  Extraction of pericardium with SDS treatment again produced a significant 
reduction in α-Gal levels (22.08 ± 5.97%) compared to glutaraldehyde fixed 
pericardium.  This was a 39.68% reduction compared to glutaraldehyde treated 
tissue.  A-Gal antigen levels, while reduced by SDS treated tissue remained 
significantly higher than the GTKO background (6.61 ± 0.68 %).  Tissues 
treated with α-galactosidase regardless of subsequent processing showed 
significantly reduced α-Gal levels with an average GIE M86 inhibition level of 9.79 
± 0.59 % (Figure 5.2A) comparable to α-Gal-free GTKO pericardium which 
ranged from 5.52% to 10.11% dependently on the anticalcification treatments.  
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The PERIMOUNT Plus 6900P bovine pericardial valve showed high levels of α-
Gal antigen with GIE M86 inhibition of 50.77 ± 5.82% (Figure 5.2B). 
 
 
 
Figure 5.2 GIE M86 estimates of α-Gal antigen on fixed porcine pericardium after 
anticalcification treatments.  A) WT pericardium (blue) was fixed with glutaraldehyde (GLUT) 
and subsequently processed with glycine for glutaraldehyde quenching, with formaldehyde–
ethanol–Tween 80 (FET), sodium dodecyl sulfate (SDS) or ethanol (EtOH) to extract 
phospholipids.  GLUT fixed pericardium was also treated with α-galactosidase to remove α-Gal 
epitopes.  Combinations of these treatments were applied as well.  GTKO pericardium (light 
blue) was similarly treated to account for non-specific M86 absorption.  Each bar represents a 
minimum of three samples.  Bars without error bars represent single samples.  The asterisk 
indicates the significantly (p<0.05) lower α-Gal levels in SDS treated tissue compared to the 
GLUT fixed tissue.  B) α-Gal antigen levels in a Carpentier-Edwards PERIMOUNT Plus 6900P 
bovine pericardial valve (purple).  Error bars represent standard error of the mean (SEM).  
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5.3 Assessment of α-Gal levels after anticalcification of porcine 
heart valves 
Heart valve leaflets consist of a three-layered structure which is more 
complex than pericardium and may be differently affected by anticalcification 
treatments.  We used the GIE GSIB-4 and GIE M86 assays to measure α-Gal levels 
in glutaraldehyde fixed pulmonary and aortic porcine heart valves after 
additional processing. 
The WT aortic and pulmonary valve leaflets did not differ in their α-Gal 
content as measured by either the GIE (GSIB-4) assay (62.33 ± 5.83 % and 64.23 
± 4.66 %, respectively) or the GIE (M86) assay (41.86 ± 3.34 and 43.28 ± 2.75, 
respectively).  None of the anticalcification treatments, including SDS extraction, 
significantly reduced α-Gal in valve leaflets (Figure 5.3A and 5.3B).  The only 
consistent reduction of α-Gal levels was due to α-galactosidase digestion alone 
or in combination with additional processing. 
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Figure 5.3 A) GIE (GSIB-4) and B) GIE (M86) estimates of α-Gal antigen on fixed porcine 
heart valves after processing with anticalcification treatments.  WT pulmonary (blue) and 
aortic (dark blue) leaflets were fixed with glutaraldehyde (GLUT) and subsequently processed 
with glycine for glutaraldehyde quenching, or with formaldehyde–ethanol–Tween 80 (FET), 
sodium dodecyl sulfate (SDS) or ethanol (EtOH) to extract phospholipids.  Alpha-galactosidase 
was used to remove α-Gal epitopes.  Treatments were applied alone or in combinations.  GTKO 
leaflets (light blue) were treated to account for non-specific lectin or M86 absorption.  Each bar 
is the mean GIE (GSIB-4) or GIE (M86) inhibition from a minimum of three samples.  Bars without 
error bars represent single samples.  Error bars represent standard error of the mean (SEM). 
 
 
 
108 
 
5.3.1 Normalization of GIE inhibition results by tissue weight 
In previous GIE assays the amount of tissue was standardized by using an 
equal number of disks produced from a 3 mm punch biopsy.  When screening 
heart valves leaflets it was evident that there was a significant variation in tissue 
thickness.  In some assays we therefore normalized the GIE inhibition results by 
the weight of the disks to account for this variation.  After the GIE assay was 
completed sample disks were dried in an incubator at 65 oC for a minimum of 
two days and then weighed using an analytical balance. 
The weights of pericardium (N=42) and valve leaflets (N=41) samples (each 
sample consisting of 8 disks) were within a range of 2.84 ± 0.08 mg and 3.97 ± 
0.17 mg, respectively.  WT aortic leaflet samples weighed significantly more 
than WT pulmonary leaflets.  Pericardium sample weights varied less (Figure 
5.4).  We therefore normalized GIE inhibition data from valves by their 
corresponding weight. 
 
 
Figure 5.4  Weights of pericardium and valve leaflets samples.  Disks (8 disks per sample) 
were dried and then their weights were determined.  The mean weight of aortic leaflets was 
significantly higher than pulmonary leaflets. 
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When the GIE GSIB-4 and GIE M86 inhibition data was normalized by weight of 
tissue none of the anticalcification treatments appeared to reduce α-Gal levels 
on valve leaflets (Figure 5.5A).  Only α-galactosidase digestion reduced α-Gal 
as indicated by the GIE M86 assay (Figure 5.5B).  No GIE GSIB-4 normalized by 
weight data was available for α-galactosidase. 
 
Figure 5.5  Normalization of A) GIE GSIB-4 and B) GIE M86 inhibition data by weight for 
valve leaflet samples.  WT pulmonary (blue) and aortic (dark blue) leaflets were fixed with 
glutaraldehyde (GLUT) and subsequently processed with glycine for glutaraldehyde quenching, 
or with formaldehyde–ethanol–Tween 80 (FET), sodium dodecyl sulfate (SDS).  Alpha-
galactosidase was used to remove α-Gal epitopes.  Treatments were applied alone or in 
combinations.  GTKO leaflets (light blue) were treated to account for non-specific lectin or M86 
absorption.  After GIE assay was completed the dry weight of samples was determined and 
used to normalize the inhibition data.  Each bar is the mean GIE (GSIB-4) or GIE (M86) inhibition 
normalized by sample weight from a minimum of three samples.  Bars without error bars 
represent single samples.  Error bars represent standard error of the mean (SEM). 
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5.4 Histochemical stain of BHVs 
GIE estimates of α-Gal antigen levels in porcine pericardium and valves, 
whether measured using GSIB-4 or M86 consistently showed little change after 
anticalcification treatment, except in the case of SDS extraction of pericardium 
where there was a significant reduction in α-Gal levels observed.  To confirm 
our GIE results histochemical stain with GSIB-4 was applied to two commercial 
BHVs, the Perimount Plus valve (treatment similar to FET) and a porcine aortic 
valve, Saint Jude Medical Epic (ethanol treatment).  Both devices stained 
strongly for GSIB-4, particularly the Epic valve, while there was no staining 
when GSIB-4 had been pre-incubated with inhibitor tri-α-Gal (Figure 5.6). 
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Figure 5.6  Detection of α-Gal on commercial BHVs.  GSIB-4 staining was applied to 
sections of commercial BHVs (top panel).  Controls with tri-α-Gal inhibition (middle panel) and 
background control with only streptavidin HRP-conjugated (bottom panel) were included.  Left 
panel- Saint Jude Medical Epic pig valve and right panel- Carpentier-Edwards Perimount Plus 
pericardial valve.   
 
Fixed pig pericardium that had been processed in the lab was also stained 
with GSIB-4 and confirmed the presence of α-Gal on tissue despite 
anticalcification treatments (Figure 5.7).  
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Figure 5.7 Detection of α-Gal on fixed pig pericardium after anticalcification processing.  
GSIB-4 staining was applied to sections of (A) fixed pig pericardium and (B) fixed pig heart 
valves.  Tissue had previously been fixed with glutaraldehyde (GLUT) and subsequently 
processed with ethanol (EtOH), glycine and ethanol (Gly + EtOH), formaldehyde–ethanol–
Tween 80 (FET), FET and glycine (Gly + FET), sodium dodecyl sulfate (SDS).  Controls with 
specific inhibitor tri-α-Gal (GSIB-4 + TRFA) were included.   
 
5.5 Summary and discussion of results 
Different anticalcification treatments similar to the ones that are used in 
commercial BHVs were applied to glutaraldehyde fixed porcine pericardium and 
valve leaflets.  Only SDS treatment significantly reduced α-Gal levels on 
pericardium, as estimated by GIE GSIB-4 and GIE M86.  One commercial 
pericardial valve (Perimount Plus 6900, Edwards LifeSciences) that contains an 
anticalcification treatment similar to FET exhibited high inhibition levels in both 
GIE GSIB-4 and GIE M86 suggesting that it expresses high levels of α-Gal.  
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Normalization of GIE inhibition results by tissue weight to account for some 
variability in valve leaflet samples, confirmed that anticalcification processing 
did not eliminate α-Gal.  Histochemical GSIB-4 staining on fixed porcine tissue 
treated in the lab and two commercial BHVs confirmed our GIE results and 
showed that all the tested tissues stained positive for α-Gal despite 
anticalcification processing. 
Anticalcification treatments mainly target phospholipids, which clearly act as 
calcification sites and their extraction greatly limits calcification in animal 
models.  The persistence of the α-Gal antigen after anticalcification treatment in 
these experimental tissues and in the commercial bovine pericardial valve may 
contribute to the absence of a clear improvement in commercial valve durability 
in younger patients treated with anticalcification processed valves.  This 
suggests that age-dependent SVD is not primarily the result of passive 
phospholipid directed calcification but may be disproportionately affected by 
immune injury.  
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6 GTKO Mice  
6.1 Establishment of double knock-out mice colony 
Heterozygous GGTA-1 BALB/c embryos from Taconic Farms were 
implanted in surrogate female mice by the UCL Institute of Child Health 
Transgenic Services unit to re-derive GTKO mice.  The offspring were 
genotyped and confirmed to be heterozygous for the GGTA-1 gene as expected 
(Figure 6.1). 
 
 
Figure 6.1  DNA electrophoresis of re-derived mice.  Agarose gel (2%) analysis of PCR 
products amplified from genomic DNA of re-derived mice.  Lane 1: 100 bp molecular weight 
ladder (M.w.), lanes 2 and 7: wild type mice controls (WT), lanes 3 - 5; 8 - 10 and 12: DNA 
samples from re-derived mice (indicated by numbers 1 – 7).  WT mice show only the 358 bp 
product produced from the normal GGTA-1 gene.  Heterozygous mice show the WT 358 bp 
product from one allele and a 235 bp product produced from the PGK-neo disrupted allele.  All 
the re-derived mice were heterozygous. 
 
Inbreeding of heterozygous mice produced offspring of all three genotypes: 
WT, HET and GTKO (Figure 6.2). 
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Figure 6.2  DNA screening of re-derived mice’s offspring.  Agarose gel (2%) analysis of 
PCR products amplified from genomic DNA from the offspring of re-derived mice.  Lane 1: 100 
bp molecular weight ladder (M.w.), lane 2: genomic WT DNA with only the 358 bp product 
produced from the normal GGTA-1 gene, lane 3: heterozygous GGTA-1 (+/-), (HET), control 
DNA with two bands corresponding to the WT 358 bp product from one allele and a 235 bp 
product produced from the PGK-neo disrupted allele and lane 4: GTKO control DNA with the 
235 bp product produced from the PGK-neo disrupted allele.  The same applies for the lower 
panel.  DNA samples from screened mice are indicated by numbers 1-24 and were either WT, 
HET or GTKO. 
GTKO male and females were chosen to breed and all their offspring were 
GTKO as confirmed by their genotyping (Figure 6.3). 
 
Figure 6.3.  Establishment of GTKO colony by inbreeding of GTKO individuals.  
Agarose gel (2%) analysis of PCR products amplified from genomic DNA of offspring from 
GTKO mice inbreeding.  Lane 1: 100 bp molecular weight ladder (M.w.), lane 2: genomic 
WT DNA with only the 358 bp product produced from the normal GGTA-1 gene, lane 3: 
heterozygous GGTA-1 (+/-), (HET), control DNA with two bands corresponding to the WT 
358 bp product from one allele and a 235 bp product produced from the PGK-neo disrupted 
allele and lane 4: GTKO control DNA with the 235 bp product produced from the PGK-neo 
disrupted allele.  All the screened mice (18-29) were GTKO. 
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Breeding couples were established to produce GTKO mice for subcutaneous 
implantation.  Offspring of each breeding group were genotyped at least once to 
confirm homozygosity.  
6.2 GTKO Mice: Production of anti-Gal 
Serum samples were collected from GTKO mice, at 40, 70, 100, 130 and 
160 days of age to measure age-dependent changes in anti-Gal antibody 
expression.  These time points were selected because they corresponded to the 
duration of pericardial implantation.  Age 40 days corresponds to the day of 
implantation and 100, 130 and 160 days correspond to 60, 90, and 120 days 
post implantation, respectively. 
GTKO mice in the absence of immunization are known to produce mainly 
anti-Gal IgM antibodies and much lower levels of IgG (Chong et al. 2000;Gock, 
Salvaris, Murray-Segal, Mottram, Han, Pearse, Goodman, Cowan, & d'Apice 
2000).  We observed serum anti-Gal antibody levels increasing with age (Figure 
6.4A).  Young mice (40 days old) produced minimal levels of anti-Gal antibody.  
Anti-Gal IgM antibody levels substantially increased in an age-dependent way 
beginning at 70 days of age.  Serum anti-Gal IgG levels, while detectable in 
some mice at 70 days, remained minimal throughout the period of study. 
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Figure 6.4  Age-dependent production of anti-Gal IgG and IgM antibodies in GTKO mice.  
Age matched GTKO mice that did not receive any implants served as serum control donors.  A) 
Serum samples were collected at 40, 70, 100, 130 and 160 days of age.  Gal ELISA analysis 
revealed an age-dependent increase in anti-Gal IgM levels (red line).  IgG levels (blue line) 
remained low during the course of the study.  B) Mice were immunized with KLH-Gal at 28 days 
of age.  Anti-Gal IgG and IgM levels were determined 130 days later.  Error bars represent 
SEM. 
 
We synthesized a conjugate of keyhole limpet hemocyanin and α-Gal (KLH-
Gal) to immunize GTKO mice to increase the level of anti-Gal IgG.  This 
conjugate was preferred, compared to rabbit red blood cells which are often 
used for this purpose (Galili, LaTemple, & Radic 1998) because it is unlikely 
that KLH-Gal shares any antigens with pig pericardium, other than the α-Gal 
antigen.  Serum anti-Gal IgG and IgM in GTKO mice 130 days after 
immunization with KLH-Gal showed highly elevated levels of anti-Gal IgM and 
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IgG (Figure 6.4B).  Average serum titres of anti-Gal IgM increased from 50.99 ± 
24.72 in age-matched unimmunized mice to 137.38 ± 34.14 in immunized mice.  
Likewise the average serum titres of anti-Gal IgG increase from 7.12 ± 3.23 in 
age matched unimmunized mice to 3283.75 ± 3225.29 in immunized mice.  It is 
evident in the IgG response that there was a large variance in serum titre 
between individuals.  One of the mice had a titre of 9734.29 compared to 
38.23.and 78.74 in the other two mice. 
6.3 Subcutaneous pericardial implantation 
Fixed WT and GTKO porcine pericardium disks were implanted 
subcutaneously in 40 day old GTKO mice as described in 2.12.3 and implanted 
tissue was recovered 60, 90 and 120 days after implantation.  Additionally 
GTKO mice were immunized with KLH-Gal by intraperitoneal injection at 30 
days of age and were implanted with WT and GTKO fixed porcine pericardium 
disks at 40 days of age.  Implantation groups are summarized in Table 3: 
Table 3  Types of implants.  WT and GTKO pericardium was implanted subcutaneously in 
GTKO mice according to the following table.  Implants were recovered 60, 90 and 120 days 
after surgery in groups (WT), (KO), (WT+Ab) and (KO+Ab) and after 120 days for immunized 
groups (WT i) and (KO i). 
Implant groups Types of implants 
WT Fixed WT pericardium 
KO Fixed GTKO pericardium 
WT + Ab Fixed WT pericardium pre-labelled with anti-Gal antibody 
KO + Ab Fixed GTKO pericardium pre-labelled with anti-Gal antibody 
WT i Fixed WT pericardium implanted in immunized mice 
KO i Fixed GTKO pericardium implanted in immunized mice 
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6.3.1 Anti-Gal immune response to subcutaneous WT and GTKO 
implants 
Implantation of α-Gal-positive fixed WT pericardium was expected to create 
an additional source of α-Gal-specific immune stimulation in GTKO recipients 
which would result in increased expression of anti-Gal antibody.  Although our 
immunization experiments showed that GTKO mice were immunologically 
competent, and capable of increased expression of anti-Gal antibody when 
challenged, the WT pericardial implant recipients did not exhibit an obvious 
response (Figure 6.5).  Serum anti-Gal IgM levels in age-matched control mice 
(not receiving an implant) and in mice 60, 90 and 120 days after implantation of 
WT pericardium were not significantly different.  Recipients of α-Gal-free GTKO 
pericardium, as expected, did not exhibit increased levels of anti-Gal antibody 
after subcutaneous implantation (Figure 6.5A).  Serum anti-Gal IgG levels in 
GTKO mice were lower and much more variable than IgM.  There was no 
induced anti-Gal IgG response to WT or GTKO pericardial implantation at any 
duration compared to non-implanted age-matched controls (Figure 6.5B).  
Indeed for 40 of the 97 implanted mice IgG anti-Gal antibodies were 
undetectable (titre < 0.1). 
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Figure 6.5  Serum anti-Gal antibody titres in GTKO mice were not significantly different 
after subcutaneous implantation of WT or GTKO pericardium compared to non-implanted 
age-matched control mice.  GTKO mice were implanted subcutaneously with fixed WT or 
GTKO porcine pericardium and the implants were recovered after 60, 90, and 120 days.  A) 
Average titre of serum anti-Gal IgM.  B) Average titre of serum anti-Gal IgG.  The results show 
no significant additional induction in anti-Gal IgM or IgG response in WT or GTKO implants 
recipients compared to age-matched animals which did not receive implants (controls).  A 
minimum of 7 samples per group was tested.  Error bars represent SEM. 
 
 
6.3.2 Anti-Gal levels in immunized pericardial implant recipients 
GTKO mice were immunized to raise their level of anti-Gal antibody prior to 
implantation of WT pericardium.  This would allow us to test whether increased 
endogenous levels of anti-Gal antibodies would accelerate tissue calcification.  
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Immunization of these pericardial implant recipients increased the serum anti-
Gal IgM and IgG but, as previously observed, this immune response varied 
wildly between individuals.  Of the 13 immunized mice which received implants, 
4 showed a modest induction of anti-Gal IgG (titres 33.3 - 395.5), 6 mice 
showed strong antibody increases (titres 1245.5 - 13,942.3) and three mice had 
no response, with undetectable levels of anti-Gal IgG.  These serum antibody 
levels in immunized WT pericardial implant recipients were comparable to what 
was observed in animal which were only immunized (Figure 6.6). 
 
 
Figure 6.6  Anti-Gal IgM and IgG antibody response after WT pericardium implantation in 
immunized GTKO mice.  GTKO mice were immunized with KLH-Gal 12 days prior to 
implantation that they received WT pericardial implants for 120 days.  Anti-Gal serum levels 
were measured on the day the implants were retrieved.  The graph depicts anti-Gal IgM (blue) 
and IgG (green) antibody levels in age-matched, immunized mice that had not received 
implants (immunized controls) and in immunized mice which had received WT pericardial 
implants (WT i).  Error bars represent SEM. 
 
 
These results, which take into account the progressive age-dependent 
increase in serum anti-Gal antibody in GTKO mice, suggest that subcutaneous 
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implants of WT fixed porcine pericardium did not present a chronic immune 
challenge to the recipients.  At 60, 90 and 120 days after implantation there was 
little evidence of a significant induction of anti-Gal IgG, even though it is evident 
by KLH-Gal immunization that GTKO mice can mount an IgG response when 
challenged.  While we would not have detected a transient early induced 
antibody response prior to 60 days post implant, these results suggest that the 
implants were effectively segregated from the immune system, such that 
chronic α-Gal-specific immune sensitization did not occur. 
6.3.3 Calcification of pericardial implants 
Previously our group had shown in rat and rabbit subcutaneous implant 
models that binding of human anti-Gal antibody to fixed α-Gal-positive tissue 
increased the level of tissue calcification.  Since GTKO mice produce low levels 
of anti-Gal antibody in this study we pre-incubated WT fixed pericardial disks 
with a mixture of mouse anti-Gal IgM and IgG as a positive control to enhance 
tissue calcification.  We also compared the calcification of WT and GTKO 
pericardium in the absence of exogenous anti-Gal antibody and in recipients 
immunized to high levels of endogenous serum anti-Gal antibody (Table 4). 
A total of 192 pericardial disks (111 WT disks and 81 GTKO disks) were 
recovered between 60 to 120 days post implant for analysis of calcium content 
using inductively coupled plasma spectroscopy.  The intrinsic calcium content 
for each type of pericardium, fixed WT (N=12) and GTKO (N=12) disks, prior to 
implantation was uniform and low showing 0.385 ± 0.101 μg/mg in WT tissue 
and slightly higher, 0.865 ± 0.511 μg/mg in GTKO tissue.  Calcium levels in the 
123 
 
implanted tissue varied widely from 0.071 μg/mg to 179.456 μg/mg.  The mean 
calcium content for WT disks was 1.73 ± 0.63 μg/mg and for GTKO disks 13.67 
± 4.24 μg/mg.  A few disks (10 out of 192), particularly GTKO disks, had high 
calcium content (> 40 µg/mg) which increased this mean value.  The vast 
majority of disks (159 out of 192) contained less than 2 μg/mg as is evident in 
the distribution of calcification for explanted pericardium (Figure 6.7). 
 
Figure 6.7  Histogram of calcification of implanted disks.  The histogram depicts the 
frequency of calcium concentrations (y axis) that were measured in the WT (blue) and GTKO 
(orange) pericardial disks after subcutaneous implantation.  Note the y axis is interrupted so that 
the distribution of samples with low frequency is clearly depicted.  The majority of disks had 
calcium levels lower than 2 μg/mg. 
 
More details about the experimental groups are listed in Table 4.   
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Table 4. Anti-Gal antibody titres and calcium content in experimental groups.  The table 
lists mean values for anti-Gal IgM and IgG titres and calcium content for the different 
implantation groups of mice according to the type of implant they received and the duration of 
implantation. 
Implant IgM titre IgG titre Calcium (μg/mg) 
WT, 60 days 32.77 ± 15.87 4.23 ± 2.91 0.31 ± 0.03 
WT, 90 days 21.43 ± 9.68 3.34 ± 2.95 1.82 ± 1.07 
WT, 120 days 31.51 ± 11.86 0.08 ± 0.04 0.88 ± 0.16 
WT+Ab, 60 days 14.26 ± 3.71 1.98 ± 0.89 0.89 ± 0.58 
WT+Ab, 90 days 29.49 ± 13.46 6.87 ± 4.99 6.58 ± 4.18 
WT+Ab, 120 days 50.65 ± 10.41 1.65 ± 1.42 1.28 ± 0.25 
KO, 60 days 23.32 ± 8.41 2.72 ± 1.75 0.45 ± 0.06 
KO, 90 days 18.74 ± 8.04 1.61 ± 1.04 27.73 ± 14.91 
KO,120 ays 63.00 ± 16.03 9.28 ± 6.13 41.15 ± 16.55 
KO+Ab, 60 days 15.16 ± 7.70 2.36 ± 1.46 2.33 ± 1.51 
KO+Ab, 120 days 590.04 ± 344.00 7.64 ± 5.54 1.25 ± 0.49 
WT immunized  
(120 days) 
37.08 ± 10.54 1991.26±1713.76 0.55 ± 0.08 
KO immunized  
(120 days) 
140.23 ± 62.18 2558.20±1133.25 6.64 ± 5.58 
Non Implanted Controls (correspond to days post implant) 
0 days 1.40 ± 1.28 0.07 ± 0.04 
 
30 days 12.89 ± 6.17 5.44 ± 3.22 
 
60 days 12.22 ± 4.16 2.06 ± 0.66 
 
90 days 34.08 ± 16.73 8.20 ± 4.14 
 
120 days 50.99 ± 24.72 7.12 ± 3.23 
 
immunized, 
(120 days) 
137.38 ± 34.14 3283.75±3225.29 
 
 
Not implanted WT disk 
 
0.39 ± 0.10 
Not implanted GTKO disk 
 
0.87 ± 0.51 
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6.3.4 Calcification of GTKO pericardial implants 
GTKO pericardium which was designed to be a negative control in these 
studies, showed minimal calcification 60 days after implantation but unusually 
high calcification at 90 and 120 days post implantation (Figure 6.8).  There was 
very high variance at these time points with only a few disks containing very 
high levels of calcium.  GTKO tissue (N=14) explanted at 90 days post 
implantation had an overall calcium concentration of 27.73 ± 14.91 µg/mg but 
this value was distorted by three samples with calcium content higher than 50 
µg/mg.  The remaining calcium values were in the range of (0.61 - 3.55) µg/mg, 
with a mean of 1.88 ± 0.29 µg/mg.  GTKO pericardial explants at 120 days post 
implantation (N=14) had a mean calcium content of 41.15 ± 16.55 µg/mg, 
significantly higher than in the non-implanted control (Figure 6.8).  However this 
mean was elevated by 4 disks with calcium higher than 100 μg/mg and 1 disk 
containing 40.38 μg/mg.  The remaining calcium values at 120 days were in the 
range of (0.47–1.78) µg/mg, with a mean of 1.29 ± 0.23 µg/mg.  Apart from the 
heavily calcified GTKO disks there was no significant increase in GTKO tissue 
calcification at any time point compared to non-implanted GTKO tissue. 
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Figure 6.8  Calcification of implanted GTKO pericardium.  Levels of calcium were 
determined using inductively coupled plasma spectroscopy on GTKO pericardium disks that 
were retrieved after 60, 90, 120 days of subcutaneous implantation in GTKO mice.  GTKO 
pericardium disks that were not implanted served as reference controls for intrinsic calcification 
of the tissue (KO, control).  GTKO pericardium implanted for 120 days had significantly (p < 
0.05) higher levels of calcium than the control.  GTKO pericardium pre-labelled with anti-Gal 
antibody (KO + Ab) did not calcify even after 120 days of implantation.  A minimum of 12 disks 
per group were tested.  Error bars represent SEM. 
 
The average calcification in GTKO pericardium at 90 and 120 days post 
implant was much higher than calcification in GTKO tissue pre-incubated with 
anti-Gal antibody at the same explant times (Figure 6.8) and higher than the 
average calcification levels observed in any of the other groups (Table 4).  
GTKO pericardial disks pre-incubated with anti-Gal antibody showed low levels 
of calcification which was not significantly different from control GTKO disks. 
We believe the high calcification of GTKO implants was an aberration clearly 
unrelated to the α-Gal antigen.  A number of possible factors might contribute to 
the irregularity in calcium content.  The subcutaneous implant model generally 
results in encapsulation of the pericardial disks.  Encapsulation could be 
variable, even within the same animal, resulting in widely variant calcification.  
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Alternatively, individual inbred mice are not all identical and minor background 
genetic variation, for example functional single nucleotide polymorphisms 
(SNPs), could influence calcification.  Likewise epigenetic variation among mice 
due to nutrition in utero could have been another factor for variation in 
calcification levels.  Environmental factors can contribute to calcification.  Many 
of our recipients required additional anaesthesia and re-suturing of the implant 
site 1 or 2 days after the initial surgery.  This may have been due to self-inflicted 
opening of the wound or to fighting between cage-mates.  The open wounds 
exposed the implants to air and to possible infection, both of which may have 
affected tissue calcification.  While no obvious infections were present at 
explant, these early events may have variably affected tissue calcification by the 
time of explant.  Apart from each separate factor combinations of the above 
might have caused the observed unusually high level of calcification in a small 
number of GTKO disks. 
6.3.5 Serum anti-Gal antibody and WT tissue calcification 
WT pericardium disks showed increased calcification at 90 days (1.82 ± 1.07 
μg/mg) and 120 days (0.88 ± 0.16 μg/mg) post implantation compared to the 
non-implanted WT tissue (0.39 ± 0.10 μg/mg).  Calcium levels after 120 days 
implantation were significantly higher than after 60 days implantation and than 
in the non-implanted WT tissue (Figure 6.9). 
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Figure 6.9  Calcification of WT pericardium.  Levels of calcium were determined on WT 
pericardium disks retrieved after 60, 90, 120 days of subcutaneous implantation in GTKO mice.  
WT pericardium disks that were not implanted served as reference controls for intrinsic tissue 
calcium.  Significantly (p<0.05) higher levels of tissue calcium were present at 120 days after 
implantation compared to the non-implanted control tissue (indicated by asterisk).  A minimum 
of 12 disks per group were tested.  Error bars represent SEM. 
 
When WT pericardium was pre-incubated with anti-Gal antibody there was a 
trend to greater calcification at all explant time points.  These differences were 
not significant (Figure 6.10).   
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Figure 6.10  Calcification of WT pericardium implants pre-labelled with anti-Gal antibody.  
GTKO mice were implanted subcutaneously with fixed porcine pericardium for 60, 90, 120 days.  
Calcium levels in the explanted disks were measured using inductively coupled plasma 
spectroscopy.  WT pericardium calcified moderately over time.  The positive control, WT 
pericardium pre-labelled with anti-Gal antibody (WT+Ab), tended to calcify more than non-
labelled pericardium (WT).  There seemed to be increase in calcification after 90 days of 
implantation for the positive control, but it was not significant, as the variance was very high.  A 
minimum of 15 disks per group were tested, except for the 90 days WT disks that consisted of 
11 disks.  “WT control” represents WT pericardium not implanted.  Error bars represent SEM. 
 
Overall there was no correlation between calcification of WT pericardium and 
antibody titres in the implant recipients (Figure 6.11).  Correlation and regression 
analysis between tissue calcium and antibody titres showed no significant 
correlation.  Pearson correlation coefficient (r) for IgM was equal to – 0.12 with 
a p value of 0.596 and r = - 0.134 for IgG with p=0.599.  A Spearman’s rank 
correlation coefficient (rs) was also calculated, since some of the data was not 
normally distributed.  This analysis also showed no correlation with rs= 0.085 for 
IgM and -0.322 for IgG.  Calcium levels in WT pericardium, for any duration of 
implantation, were in the range of (0.07-1.87) μg/mg with the exception of only 
one disk which contained 12.36 μg/mg.  Even when this data point was 
excluded there was no correlation between calcification of implants and anti-Gal 
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IgM (rs= 0.119) or IgG (rs= - 0.307) response.  It seems that the generally very 
low level of calcification detected in this study using GTKO mice is unrelated to 
anti-Gal antibody reactivity and is not analogous to the strong α-Gal-specific 
antibody induced calcification we previously observed in rats and rabbits. 
 
 
Figure 6.11  Relationship between anti-Gal antibody response data and calcification data 
for WT pericardium implants.  GTKO mice were implanted subcutaneously with fixed porcine 
pericardium for 60, 90, 120 days.  Calcium levels were determined in the explanted disks using 
inductively coupled plasma spectroscopy and anti-Gal antibody levels were estimated by Gal 
ELISA.  There was no correlation between calcium levels and serum anti-Gal IgM (A), 
(rs=0.085), or IgG (B), (rs= - 0.322) response at any duration of implantation with most samples 
containing very low levels of calcium.  A minimum of 15 disks per group were tested, except for 
the 90 days group that consisted of 11 disks. 
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The lack of correlation between implant calcification and levels of 
endogenous antibody, the absence of an induced anti-Gal immune response in 
WT implant recipients and the small impact of exogenous antibody incubation 
with the tissue prior to implant (Figure 6.10) suggest that the implants were 
isolated from the immune system, did not cause chronic α-Gal stimulation.  This 
model may have restricted endogenous antibody from reaching the implant and 
did not lead to extensive tissue calcification. 
6.3.6 Effect of immunization on calcification of implanted 
pericardium 
Mice were immunized against α-Gal in order to increase serum anti-Gal 
antibody levels and possibly enhance the effect of anti-Gal antibody on 
calcification of WT pericardium.  Calcification of WT implants in immunized mice 
was not increased compared to WT pericardium implanted in naïve mice 
(Figure 6.12). 
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Figure 6.12  Immunization of GTKO mice did not induce calcification of WT pericardium.  
GTKO mice were immunized with KLH-Gal and 12 days later they were implanted 
subcutaneously with WT pericardium for 120 days.  Calcium levels in WT implants (WT- 
immunized) were not enhanced compared to the calcification in non-immunized mice (WT).  A 
minimum of 15 disks per group were tested.  Error bars represent SEM. 
 
6.3.7 Inflammatory response 
Hematoxylin and eosin staining was done on some explanted disks, focusing 
on those with high levels of calcium (> 100 µg/mg) and on disks with low 
calcium levels (< 2µg/mg).  Sections of this material showed a thin surface 
encapsulation of the pericardial disks.  The encapsulating layer was cellular and 
likely consisted of macrophages and monocytes, although no specific staining 
was performed to verify cell identity.  In the limited number of tissues examined 
we did not detect any clear association between the extent of encapsulation and 
tissue calcification (Figure 6.13A).  Disks with high calcium levels (determined 
by inductively coupled plasma spectroscopy) were stained with Von Kossa to 
detect for calcium.  The Von Kossa stain makes a dark granular pigmentation in 
the presence of calcium.  There was no calcium staining in these sections 
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(Figure 6.13B).  This may be due to biopsy sampling error as the explanted 
disks showed no macroscopic evidence (nodules or hardness) of calcification. 
 
 
Figure 6.13  Histology results on selected pericardial explanted disks.  Explanted 
pericardial disks with average calcification (1ug/mg) and highly calcified (120 and 115 ug/mg) 
disks were selected for staining.  A) Hematoxylin and eosin stain.  B) Von Kossa stain.  There 
was a thin surface cellular encapsulation of the pericardial disks, most likely consisting of 
macrophages and monocytes (arrows).  Pericardium is indicated by “p”.  There was no positive 
calcium staining. 
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6.4 Summary and discussion of results  
GTKO mice are immunologically competent exhibiting an age-dependent 
increase in anti-Gal IgM levels and low levels of IgG.  Immunization by KLH-Gal 
resulted in an induced anti-Gal IgM and IgG response, although the anti-Gal 
IgG titres were highly variable between individuals.  Subcutaneous implants of 
fixed WT tissue did no induce an anti-Gal IgG or IgM response after 60, 90, 120 
days beyond that accounted for by the recipient’s age.  This suggests that the 
implanted tissue was sequestered from the immune system and therefore did 
not act as an antigenic stimulator for the recipients. 
WT and GTKO pericardium implants showed increased calcium content at 
90 and 120 days post implantation compared to control non implanted disks.  
Most disks (159 out of 192 disks) showed relatively low levels of calcification 
(lower than 2 µg/mg).  Only 6 out of 192 disks showed very high calcification 
(higher than 100 µg/mg).  These exceptional disks were GTKO pericardium 
implanted for 90 days (2 disks) and 120 days (4 disks).  
A possible explanation for the very low calcification and the lack of antibody 
response to WT pericardium is that the implanted disks appeared to be 
sequestered from the immune system.  The implants in this model were largely 
unaffected by both exogenous and endogenous anti-Gal antibody, contrary to 
our experience in the subcutaneous rat model.  Implantation of WT pericardium 
in immunized mice did not induce additional calcification compared to that in 
naive recipients.  This suggests that circulating antibody was not getting to the 
graft.  Exogenous antibody pre-labelling had some effect on WT pericardium, 
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which calcified more compared to unlabelled pericardium but the impact was 
small.  
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7 Discussion 
Demand for heart valve replacement continues to increase due to ageing of 
global population.  Emergence of improved healthcare in developing nations is 
likely to further increase demand for heart valve replacement.  BHVs are often 
preferred to mechanical valves as they generally do not require anticoagulation, 
however their rapid degeneration in young adults and children limits their utility 
(Zilla et al. 2004).  There has been extensive research to optimize valve design, 
tissue fixation and processing, but little attention has been directed to the 
contribution of immune mediated injury to BHV degeneration.  This may be 
because glutaraldehyde fixation was widely believed to eliminate any BHV 
immunogenicity.  
Relevant to immune injury is the fact that commercial BHVs express the 
dominant xenogeneic antigen α-Gal.  Humans and Old World primates 
universally produce anti-Gal antibody and this carbohydrate antigen remains 
immunogenic in patients, especially young adults and children (Galili 1999).  
Patients exhibit induction of anti-Gal antibody after BHV implantation (Konakci 
et al. 2005;Park et al. 2010).  In experimental models anti-Gal antibody is 
sufficient to accelerate calcification of fixed bioprosthetic tissue (Lila et al. 
2010;McGregor et al. 2011).  These observations suggest that antibody induced 
immune injury may have a significant contribution to age-dependent BHV 
calcification and degeneration.  Antibody mediated inflammation is consistent 
with the histopathology of an inflammatory response present in normal BHVs 
recovered from LVADs prior to tissue calcification and SVD.  Macrophages 
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mainly infiltrate the tissue, with antibodies, B and T cells also present but 
without accompanying severe calcification or leaflet tears of the valve.  This 
suggests that BHVs with reduced antigenicity, lacking the dominant xenogeneic 
carbohydrate antigen α-Gal, will reduce this inflammatory response and 
possibly improve BHV durability.  A durable calcification resistant BHV would be 
a significant contribution to cardiovascular therapy especially for younger 
patients, who show a disproportionately large increase in anti-Gal antibody after 
BHV implant surgery compared to older patients (Park et al. 2010) and patients 
in developing nations where anticoagulation management, required for MHVs, 
may be difficult. 
Understanding the role of α-Gal antigen in tissue calcification and developing 
α-Gal-free BHVs with reduced antigenicity requires methods to measure α-Gal 
on solid substrates.  Assays to measure α-Gal antigen on tissue can be used to 
understand the impact of current commercial anticalcification processing and 
valve durability especially in younger patients.  In this project I tested two 
methods to assess α-Gal content of tissue and using a GTKO mouse 
subcutaneous implant model further tested the relationship between anti-Gal 
antibody, tissue α-Gal content and tissue calcification.  
The α-Gal content in tissue is most frequently assessed by immunohistology 
or immunofluorescence staining of sections, primarily done with GSIB-4 lectin.  
There is some variability in the literature in reports from different groups 
regarding the presence of α-Gal on pig endothelial cells (Chen et al. 
2000;Farivar et al. 2003) and its levels of expression in BHV tissue matrix 
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(Konakci et al. 2005;McGregor et al. 2011;Naso et al. 2011).  This variability 
may result from different staining conditions, the most important of which is the 
requirement for calcium ions for α-Gal-dependent GSIB-4 binding.  Additionally, 
many studies are poorly controlled and may not accurately assess background 
GSIB-4 staining.  Our GSIB-4 staining of porcine pericardium and cardiac 
valves, using α-Gal inhibition and GTKO tissue as controls for non-specific 
background binding, shows widespread α-Gal expression on porcine valve 
endothelial cells and staining of extracellular matrix materials in α-Gal-positive 
tissues but not in GTKO tissues.  We also see similar diffuse α-Gal specific 
staining with M86 (data not shown). 
Tissue staining methods are useful to define the morphology of α-Gal 
expression but they are generally speaking not quantitative.  I used WT 
(GT+/+), heterozygous (GT+/-) and α-Gal free (GTKO) porcine pericardium and 
heart valves to test the utility of an enzymatic assay to detect α-galactosidase 
liberated galactose and a α-Gal specific inhibition ELISA assay.  The enzymatic 
detection of α-Gal was an extension of a method previously reported to 
characterize polymeric α-Gal conjugates (Byrne et al. 2002) which was based 
on commercial methods to detect lactose.  This commercial method coupled β-
galactosidase hydrolysis of lactose, to release galactose, with galactose 
dehydrogenase (GH) to produce NADH which is released in direct 
stoichiometric proportion to the amount of galactose (Essig & Kleyn 1983).  We 
substituted β-galactosidase with α-galactosidase to hydrolyse the terminal 
alpha-linked galactose from the α-Gal antigen on tissue.  In this first and 
simplest of iterations the spectrophotometric detection of NADH was insensitive 
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requiring concentration of 312 μM galactose or higher.  This is equivalent to 
approximately 1.8 x1020 molecules of galactose.  Since previous estimates of α-
Gal levels on pig tissue were in the order of 1011 residues per mg (Stone et al. 
2007) the spectrophometric detection of NADH would require in excess of 1800 
kgrams of tissue to liberate sufficient galactose for detection by this method.  To 
improve sensitivity we tried to couple the galactose dehydrogenase reaction 
with a NAD/NADH coupled enzymatic cycling assay designed for measuring 
tissue NAD or NADH (CycLex, MBL).  The CycLex NAD/NADH system is 
basically an amplifier which is “ignited” by the presence of NAD or NADH.  This 
assay has the potential to detect as little as 0.0156 µM NADH corresponding to 
9.4 x1015 molecules, a 2000-fold increase in sensitivity compared to the 
spectrophotometer which in principle would require only (10 – 100) mg of cells 
or tissue. In practice however when coupled to the GH hydrolysis of galactose 
we could only achieve an approximately 300-fold increase in overall sensitivity.  
The limited sensitivity of this GH assay may have been due in part to the need 
to eliminate high levels of NAD required for the GH reaction prior to the CycLex 
reaction, a suboptimal GH reaction or an inhibition of the CycLex system’s 
reactions by components of the GH reaction. We reasoned that the addition of 
an extra enzymatic step, that of α-galactosidase, and the need to scrupulously 
deplete NAD/NADH from tissue would inevitably further decrease the system’s 
sensitivity, so the approach was abandoned. 
As an alternative to the enzymatic detection of galactose we established a 
robust quantitative α-Gal-specific inhibition ELISA (GIE) method to measure α-
Gal on solid substrates using two different α-Gal specific reagents, the lectin 
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GSIB-4 (GIEGSIB-4) and anti-Gal IgM monoclonal antibody M86 (GIEM86).  GIE 
includes two sequential steps, firstly incubation of sample with anti-Gal reagent 
and secondly measurement of remaining anti-Gal reactivity in the supernatant 
by Gal ELISA.  Based on their reactivity in the Gal ELISA these reagents have 
distinct avidity for the α-Gal antigen.  The pentameric M86 exhibited high avidity 
for BSA-Gal with an IC50 equivalent to 2089 μM of free α-Gal trisaccharide. 
(Figure 4.2).  In comparison the IC50 in the Gal ELISA for the lectin GSIB-4 was 
much lower (323 μM).  This shows that under these conditions approximately 
6.5-fold more α-Gal trisaccharide was required to block M86 binding to BSA-Gal 
compared to GSIB-4.  The IC50 is a relative measurement of avidity, as the 
precise value will depend strongly on the concentration, accessibility and 
density of α-Gal in the ELISA assay, the method of detection in the ELISA (see 
“Materials and Methods”) and the affinity and valency of M86 and GSIB-4 
(Byrne et al. 2002).  As both anti-Gal antibody (Parker et al. 1996) and lectin 
GSIB-4 (Goldstein et al. 1981) affinity for α-Gal is reported to be in the 
micromolar range, this suggests that the IC50 differences in our experiments 
are mainly due to differences in valency between M86, with 10 binding sites and 
GSIB-4 with 4 binding sites.  
Despite apparent differences in overall avidity M86 and GSIB4 showed 
similar binding to α-Gal-positive (GT+) PAECs and similar inhibition in the GIE.  
For M86 we showed that approximately 1.6x106 GT (+) PAECs (Table 1) were 
required to inhibit 50% of M86 binding in the GIE.  A similar number of cells 
(1.3x106) produced 50% inhibition of GSIB-4 binding.  This suggests that under 
these conditions both reagents react with the PAEC surface in similar fashion.  
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In the case of fixed porcine pericardium however, GSIB-4 appeared to bind 
more effectively than M86.  This conclusion is based on two observations.  
Firstly, we consistently observed greater inhibition of GSIB-4 by fixed GT(+/+) 
pericardium compared to M86 (Figure 4.11).  Secondly, the GIEGSIB-4, but not 
GIEM86, detected a significant difference in inhibition between GT(+/+) 
pericardium and GT(+/-) pericardium (p<0.001, Figure 4.9) suggests that GT(+/-) 
tissue contains lower levels of α-Gal.  This is consistent with reports of reduced 
Gal-transferase activity in liver, lung, spleen and testis tissues of GT(+/-) pigs 
compared to those of GT(+/+) pigs (Park et al. 2012).  Under the same 
conditions GIEM86 detected a reduced level of inhibition by GT(+/-) tissue, but 
this was not significantly different from GT(+/+) tissue.  In these pericardial 
experiments, compared to the results for PAECs, the difference between these 
two reagents might be attributed to the smaller size of GSIB-4, 114kDa, 
compared to ~970kDa for M86.  Smaller size may allow GSIB-4 greater access 
to α-Gal epitopes in the tissue matrix.  One way to circumvent the accessibility 
issues would be mincing of the tissue (Naso et al. 2011) however, the biological 
significance of deeply embedded α-Gal antigen, which is only detectable after 
tissue disruption, is unclear.  Carbohydrate binding can also be affected by the 
topological presentation of oligosaccharides (Bovin et al. 2012).  If the 
presentation of α-Gal epitopes in a matrix of fixed pericardium and on the cell 
surface is subtly different then this might differentially affect GSIB-4 and M86 
binding. Given the expense of M86 and the apparently improved sensitivity of 
the GIEGSIB-4 assay the lectin based detection of α-Gal antigens seems 
preferable. 
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Other groups have used M86 in an α-Gal inhibition ELISA to analyse α-Gal 
expression on tissue (Galili et al. 1998;Naso et al. 2011).  These studies use a 
distinctly different set of conditions in their assay (both between each other and 
compared to ours) and report their results as the number of α-Gal epitopes per 
cell or epitopes per mg of tissue.  We have concerns about these methods and 
the appropriateness of reporting the results in this format.  In studies by Naso 
and colleagues the primary incubation of M86 with tissue is performed at 37oC, 
for 2 hours.  This high temperature, short incubation condition is not sufficient to 
reach equilibrium binding consistent with our observation of substantial 
increases in GIE inhibition between overnight and 48 hour primary incubation.  
It is also well known that protein and carbohydrate binding is relatively weak 
and is more stable at lower temperature.  The non-equilibrium, high temperature 
conditions used by Naso render their assay relatively insensitive.  This group 
also reports their results in terms of α-Gal epitopes per mg of wet tissue.  This 
has the appearance of accuracy but is more likely misleading and inaccurate as 
the numbers are based on historical analysis by Galili (Galili et al. 1988b) using 
the GSIB-4 lectin under distinctly different assay conditions.  In his initial study, 
Galili estimated the number of α-Gal epitopes on rabbit RBCs using a classic 
radioimmune assay format (RIA) to be 150,000 epitopes/cell (Galili et al. 1987).  
This analysis was performed using radiolabelled GSIB-4 with a primary 
incubation at 37 oC, for 1 hour.  Concerned about the stability of lectin binding 
Galili reported a second RIA study in which the primary incubation with 
radiolabelled GSIB-4 was performed at 4 oC, for 1 hour.  This analysis gave 
estimates of 10x106 α-Gal epitopes/ PAEC and 1.2x106 epitopes/mouse SP2/0 
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cell line (Galili et al. 1988b).  No estimate of rabbit RBCs was reported in this 
study.  Subsequently Galili described an M86 based GIE with primary overnight 
incubation at 4 oC (Galili et al. 1998).  This study used the SP2/0 cell line 
estimate of 1.2 x 106 epitopes / cell (defined earlier by GSIB-4 RIA incubated at 
4oC for 1 hour) as a reference standard to estimate epitope density based on 
the M86 inhibition ELISA.  This yielded estimates of 25x106 epitopes/ PAEC 
and 2x106 epitopes/ rabbit RBC.  These values are about 2 and 13-fold higher 
than in previous studies (PAEC; 1x107/ cell estimated with lectin at 4 oC for 1 
hour and rabbit RBCs of 150,000/ cell estimated with lectin at 37 oC for 1 hour).  
Galili correctly points out that the lower values for these cells were based on 
GSIB-4 binding but fails to note that the reaction conditions of the previous 
studies also would be expected to under estimate the epitope density.  Despite 
this, he and subsequently Naso and colleagues, adopt the value of 1.2x106 
epitopes per SP2/0 myeloma cells (defined by GSIB-4 at 4 oC for 1 hour) as a 
reference standard and multiplier for subsequent GIE studies.  This practice of 
extrapolating from historic antigen densities based on GSIB-4 RIA assays 
performed under completely different assay conditions to calculate number of α-
Gal epitopes based on a GIE using M86 does not seem supportable. 
Naso has also used the SP2/0 benchmark of α-Gal density on cells to 
estimate α-Gal epitope density in BHV leaflets (Naso et al. 2011).  We have 
shown that M86 and GSIB-4 exhibit similar inhibition profiles for binding to cells, 
but show differential binding to fixed pig pericardium.  While the tissue in Naso’s 
study was disrupted, it remains to be determined if a direct extrapolation about 
the number of α-Gal epitopes from cells to tissue is justified.  In conclusion we 
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believe that the α-Gal inhibition ELISA, in its current form, provides a relative 
measurement of α-Gal epitopes as originally stated by Galili (Galili et al. 1998). 
The sensitivity of the GIE was further defined by estimating the smallest 
detectable reduction in α-Gal levels on PAECs in comparison to quantitative 
flow cytometry.  We used α-galactosidase digestion to partially remove α-Gal 
epitopes from the surface of PAECs and compared the reduction in α-Gal levels 
as estimated by FACS and by our GIE assay in parallel (Figure 4.16).  FACS 
analysis consistently detected a minimum 12% reduction in α-Gal levels as 
estimated by mean fluorescence.  The smallest change in α-Gal levels that 
could be detected by GIE GSIB-4 was approximately a 20% reduction as 
estimated by FACS.  This suggests that moderate reductions in α-Gal levels 
can be distinguished by the GIE and encouraged us to use this method to 
detect differences in α-Gal levels on animal tissue after anticalcification 
treatments. 
We used a variety of anticalcification processing methods to see if they 
reduced the level of α-Gal antigen on fixed porcine pericardium and on porcine 
heart valves.  These included glutaraldehyde capping, used by Carpentier-
Edwards, ethanol, used by St. Jude Medical, Formalin-Ethanol-Tween 
extraction, used by Carpentier Edwards and extraction with SDS, used by 
Medtronics.  None of these processes eliminated α-Gal from tissue and only 
SDS treatment led to a moderate reduction of α-Gal levels on pericardium.  This 
result was consistently observed with either GIE GSIB-4 (27% reduction) and GIE 
M86 (39% reduction) assay.  We also measured α-Gal levels in a PERIMOUNT 
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Plus BHV from Edwards LifeSciences where we found high levels of α-Gal 
despite being treated with a processing similar to FET.  Although we had no 
control for fixed untreated bovine pericardium the inhibition levels of the 
Perimount tissue were unquestionably high and our FET studies on porcine 
pericardium showed no evidence of substantial α-Gal reduction suggesting that 
this commercial processing, like our experimental studies, did not substantially 
reduce α-Gal levels.  Only α-galactosidase digestion resulted in very low α-Gal 
levels compared to untreated tissue.  These GIE results were further supported 
by immunohistochemical staining of the pericardium after anticalcification 
treatment.  In each case strong α-Gal-specific GSIB-4 lectin binding was 
detected (Figure 5.1).  My results suggest that anticalcification processing does 
not eliminate α-Gal from bioprosthetic tissue.  SDS treatment, the only 
treatment that moderately reduced anti-Gal binding to fixed tissue in our assay, 
is used for extraction of phospholipids in commercial BHVs, Medtronic models 
Hancock II and Hanckock II Ultra.  The Hancock II, was first introduced in the 
market in 1982 and has excellent performance and durability in elderly 
recipients, where 20 year freedom from reoperation for aortic valve replacement 
is 86.8% in patients over 60, while in patients younger than 60 years of age it is 
52.2% (Valfre et al. 2010).  In contrast in a study on Hanckock II heart valve 
replacement which included younger patients the 20-year freedom from 
reoperation in the aortic position due to SVD was only 14.1 ± 8.7% in patients 
under 40 years of age, 21.5 ± 8.5% in patients aged 40-49 and 41.4 ± 8.2% in 
patients between 50 and 59 (P = 0.04) (Une et al. 2014).  This age-dependent 
SVD suggests that although anticalcification treatments minimize calcification in 
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animal models, they have not resolved the problem of accelerated SVD in the 
young.  This is consistent with the insufficient elimination of α-Gal antigen by 
anticalcification processing and an immune injury model of SVD. 
Naso and colleagues used their inhibition ELISA to measure α-Gal on five 
modern bovine and two porcine commercial BHVs (Naso et al. 2013a).  In this 
study native (unfixed) bovine and porcine pericardium or native porcine aortic 
leaflets were used as controls.  These tissues had reported α-Gal levels of 26 x 
1010, 18.2 x 1010, and 12 x 1010 epitopes/mg of wet tissue respectively.  In 
contrast they reported a range of (0.025 - 6.62) x 1010 α-Gal epitopes per 10mg 
of wet tissue for the bovine pericardial valves and (0.05 – 5.2) x 1010 for the 
porcine valves.  For the St Jude Epic valve, treated with LinxAc anticalcification, 
they detected 0.05 x 1010 α-Gal epitopes per 10mg (Naso et al. 2013b).  These 
results suggest that anticalcification treatments significantly lower the level of α-
Gal antigen on commercial devices.  This conclusion however must be 
interpreted in light of our previous discussion concerning the sensitivity of their 
assay. 
The importance of anti-Gal antibody in the degeneration of BHVs has not 
been appreciated in part because the animal models used for testing new 
bioprosthetic materials treatments have been performed in species that do not 
produce anti-Gal antibody.  GTKO mice produce anti-Gal antibody and would 
appear to be immunologically an ideal model to study the effect of circulating 
anti-Gal antibody on tissue calcification.  During the course of this project 
another group headed by Yon Jin Kim at the Sejong General Hospital in the 
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Republic of Korea reported on a series of comparisons of subcutaneous 
implantation studies in WT and GTKO mice (Kim et al. 2015a;Kim et al. 
2015b;Lee et al. 2012;Lim et al. 2013).  These studies are reported below. 
In their initial study Lee and colleagues reported that subcutaneous 
implantation of WT glutaraldehyde fixed bovine pericardium significantly 
increased anti-Gal IgG and IgM in GTKO mice over a 2-month course of 
implantation and that higher levels of tissue calcification occurred in GTKO 
recipient mice (0.77 µg/mg) compared to WT mice (0.12 µg/mg).  They 
concluded that WT bovine pericardium resulted in an induced antibody 
response in GTKO mice with a tendency to calcification (Lee C et al. 2012).  In 
a follow up study (Lim HG et al. 2013) they extended the duration of 
implantation (3 months) and immunized GTKO recipient mice with rabbit RBCs 
to enhance antibody effect on calcification.  Tissues treated with α-
galactosidase to remove antigenicity were also included in the study.  Anti-Gal 
IgG and IgM levels in both immunized and unimmunized mice were reported to 
have increased significantly due to implantation of fixed WT bovine pericardium 
and GTKO recipient mice showed higher levels of tissue calcification (1.85 ± 
0.97 µg/mg) compared to WT recipient mice (0.44 ± 0.22 µg/mg).  Immunization 
did not significantly affect tissue calcification (2.31 ± 1.02 µg/mg in naïve GTKO 
recipients compared to 1.85 ± 0.97 µg/mg in immunized mice).  Antibody titers 
and calcification were lower in the groups that received treated tissue.  The 
writers reinforced their hypothesis that immune response may cause 
calcification.  In a third complex study including pericardium, aortic valve and 
aortic wall of bovine and porcine origin increased titers were reported for anti-
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Gal IgM and IgG in GTKO mice (compared to WT recipients) at 30 and 60 days 
after implantation, respectively.  Calcification of all types of implants was 
significantly higher in GTKO mice compared to WT mice.  The authors 
suggested that there was more chronic immune response to the α-Gal antigen 
on bioprosthetic tissue in GTKO mice than in WT mice which resulted in higher 
calcification of the implants (Kim M-S et al. 2015).  In a final report (Kim, MS et 
al. 2015) using 4-month subcutaneous implantation in GTKO mice they included 
primate pericardium in their experiments, which does not express α-Gal.  
Enhanced calcification was reported for the bovine pericardium (9.21 µg/mg) 
compared to the primate pericardium (3.86 µg/mg). Increased anti-Gal IgG 
response was reported in bovine pericardium recipients but not in primate 
implant recipients.  These results reinforced the notion that an α-Gal-specific 
immune response to the implanted tissue enhanced calcification of the α-Gal-
positive tissues, but not α-Gal-free primate tissue. 
In this study I used GTKO mice recipients implanted with WT and GTKO 
fixed porcine pericardium for 60, 90 and 120 days.  To ensure accessibility of 
anti-Gal antibody to the tissue, WT fixed pericardial disks were pre-incubated 
with a mixture of mouse anti-Gal IgM and IgG as a positive control for enhanced 
tissue calcification.  This antibody pre-treatment was expected to induce strong 
calcification of WT tissue implants independent of the serum anti-Gal levels in 
the recipient mice.  I also immunized recipients with KLH-Gal to increase 
endogenous serum anti-Gal antibody levels, expecting this antibody to similarly 
enhance calcification of WT tissue compared to unimmunized recipients. 
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In my study, in contrast to the studies outlined above, I did not see evidence 
of an induced anti-Gal immune response caused by the implanted tissue.  I 
used a highly specific α-Gal ELISA to detect anti-Gal antibody in mouse serum.  
This analysis included M86 (for IgM analysis) or GT5 (for IgG analysis) 
reference controls to account for plate to plate and day to day variation and 
competition with free α-Gal trisaccharide to show specific α-Gal reactivity of 
mouse IgG which showed a high background to BSA.  The serum anti-Gal 
antibody levels were also measured in age matched mice without implants to 
account for the age-dependent increase in anti-Gal.  This analysis showed there 
to be an age-dependent increase in serum anti-Gal antibody in the GTKO 
recipients (Figure 6.4).  When this age-dependent increase in serum anti-Gal 
antibody is accounted for implantation of fixed porcine WT pericardium it did not 
induce an appreciable anti-Gal antibody response as measured 60, 90 and 120 
days after implantation.  Consistent with this there was no significant difference 
in the serum anti-Gal antibody levels between GTKO mice with WT or GTKO 
implants.  These results suggested that the implants did not cause chronic 
immune α-Gal stimulation and did not induce an α-Gal-specific antibody 
response. This suggests that the implants may have been rapidly sequestered 
from the immune system soon after implantation, thereby limiting the immune 
response.  A possible induced response earlier than 60 days after implantation 
cannot be eliminated, but the lack of elevated anti-Gal levels at 60, 90 and 120 
days clearly suggests that there was no chronic immune stimulation of B-cells 
due to the implants.  Similarly, in contrast to the results of the Kim group WT 
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pericardium did not induce an immune response in immunized mice beyond the 
antibody response in immunized non implanted mice (Figure 6.6). 
The GTKO mice were able to mount an induced anti-Gal IgM and IgG 
antibody response when immunized with KLH-Gal.  This induced response 
showed a high degree of individual variability, especially for anti-Gal IgG.  A 
second boost of KLH-Gal immunization might have raised higher, more 
consistent anti-Gal antibody responses, but we anticipated that implantation of 
WT porcine pericardium would function as an efficient secondary boost.  The 
comparison of serum anti-Gal levels in immunized control (not implanted) and 
implanted mice indicate that the implant did not substantially boost the immune 
response, again suggesting that the implants were not accessible to the 
immune system at an early stage.  Robust immunization against α-Gal in GTKO 
mice has been reported using rabbit RBCs membranes (Gock et al. 2000).  This 
may have been a more effective immunogen than KLH-Gal, however we did not 
want to use rabbit RBCs due to concerns that they carry additional antigens, 
other than α-Gal, that might be shared with porcine pericardium. 
In our study calcium levels in explanted WT and GTKO pericardial disks at 
all time points were higher than in the non-implanted controls (Figure 6.8, Figure 
6.9 and Table 4).  Calcium levels in WT disks were significantly higher after 120 
days implantation (0.88 ± 0.16 μg/mg) compared to control disks (0.39 ± 0.10 
μg/mg).  This level of calcification was however much lower than what we 
detected in previous subcutaneous rats studies where tissue calcification of 74 
± 9.6 μg/mg 3 weeks (McGregor et al. 2011) and 155.7 ± 7.1 μg/mg one month 
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of subcutaneous implantation (Lila et al. 2010) were observed.  We also pre-
labeled WT pericardium with anti-Gal antibody as a positive control for antibody 
induced calcification.  This treatment appeared to increase calcification 
compared to unlabeled WT implants for all post-implant durations, but these 
differences were not significant.  Consistent with previous studies we found that 
immunization did not significantly induce calcification of WT implants compared 
to calcification in naive mice. 
Summarizing our findings in the GTKO mice model, WT pericardial implants 
showed increased calcification over time and even higher calcification when 
they were pre-labelled with anti-Gal antibody.  Lack of correlation between 
implant calcification and levels of endogenous antibody both in naïve and 
immunized recipients supports the notion that the implants were isolated from 
the immune system early on, did not cause chronic α-Gal stimulation and 
endogenous serum antibody did not reach the implant.  We were disappointed 
that a stronger antibody dependent calcification was not evident in the pre-
labelled positive controls of this study but this seems to be mainly due to the 
mouse model where inherently lower levels of calcification occur compared to 
rats and the implants do not seem to induce a chronic stimulation.  Consistent 
with this conclusion macroscopic examinations of the disks from the GTKO 
mice showed only minor encapsulation (Figure 6.13), the disks were nearly 
stuck to the animal’s skin and when recovered were thin and soft.  These 
findings were different compared to implants retrieved from previous studies in 
rats and rabbits, where the disks had a larger encapsulation reaction and there 
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was palpable evidence of calcification as the disks were granular, harder to the 
touch. 
7.1 Future investigation/ studies 
This project identified a reliable method to measure α-Gal levels on animal 
tissues and indicated that GTKO mice, while able to produce anti-Gal antibody 
endogenously, have a lower tendency to calcification than observed in juvenile 
rats or rabbits.  While our group’s previous results support a role of antibody in 
inducing calcification of fixed tissue this project’s results suggest that in GTKO 
mice the subcutaneous implants are sequestered from the immune system, 
minimizing calcification and the impact of endogenous or exogenous antibody.  
This minimal calcification limits the utility of the GTKO mouse model.  Juvenile 
rats have been extensively used for studying calcification of bioprosthetic 
materials and calcify heavily in a short period of time.  It may be advantageous 
therefore in future experiments to produce GTKO rats, which like GTKO mice 
and GTKO pigs would be expected to produce anti-Gal antibody and repeat 
these subcutaneous implantation studies in these animals.  This model with 
predictable rate of calcification would allow us to study the effect of circulating 
anti-Gal antibody on tissue calcification using shorter duration of implantation.   
Valve implantation studies have traditionally been performed in the sheep 
model to assess valve function and tissue calcification.  Standard sheep 
however do not make anti-Gal antibody.  GTKO pigs are already used in 
xenotransplantation studies and could be used as valve recipients.  In addition 
there are more anatomical and physiological similarities between pigs and 
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humans.  Pigs have comparable coagulation and inflammatory systems to 
humans.  Although valve implantation surgery in pigs is a very demanding 
procedure due to pigs aversion to cardiopulmonary bypass (Mohiuddin et al. 
2015), there has been progress in optimizing anaesthesia and anticoagulation 
problems (Li et al. 2007).  Implantation of bioprosthetic mitral valves in juvenile 
pigs showed that the implanted valves functioned up to 6 months and 
calcification, histological examination and echocardiographic data showed that 
this model was comparable with the sheep model (Honge et al. 2011).  
Substituting GTKO pigs as the recipients would allow us to study the effect of 
anti-Gal antibody on calcification of BHVs in a functional large animal model 
with a more accurate representation of the human immune system with respect 
to the anti-Gal antibody.  Commercial porcine BHVs (for example Medtronic 
Mosaic, Edward Lifesciences Prima) expressing the α-Gal antigen could be 
implanted into GTKO and WT pigs to compare the impact of anti-Gal antibody 
(present only in the GTKO pig recipients) on early BHV inflammation (Konakci 
et al. 2005). 
Xenotransplantation studies have also identified other xenogeneic 
carbohydrate antigens beyond α-Gal, such as Neu5Gc and SDa.  These 
antigens are expressed on GTKO heart tissue (Park et al. 2012).  It would be 
enlightening to incorporate in our study the role of these antigens along with α-
Gal in the calcification of bioprosthetic material.  Triple knock-out pigs that do 
not express any of these three epitopes are already available (Estrada et al. 
2015), although there is as yet no information on whether they express the 
corresponding antibodies. 
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Future studies focusing on the immune response aspect of BHV 
degeneration will help towards development of more durable valves in young 
adults and children allowing them a more active way of life with fewer re-
operations. 
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